image_name
stringlengths 68
68
| type
stringclasses 2
values | gt_table
stringlengths 116
12.6k
|
|---|---|---|
dcf2158047ec3ed7ccb8e8ec5edd4ea7c0af3d994d79391f511a5fff47c6e03d.png | simple | <table><tr><td></td><td>Apical segment</td><td>Middle segment</td><td>Basal segment</td></tr><tr><td>Wild-type</td><td>207 ± 50</td><td>253 ± 23</td><td>247 ± 27</td></tr><tr><td><i>ugt78d2</i></td><td>194 ± 17</td><td>118 ± 14*</td><td>142 ± 18*</td></tr></table> |
84f5c494afb3495a9fed43198121f889e7824c98916c3ab405e46aebd1dc8e0f.png | simple | <table><tr><td></td><td>Feasibility (% of <i>n</i> = 50 valid)</td><td>Number (test-retest)</td><td>Visit 1, mean (SD)</td><td>Visit 2, mean (SD)</td><td><i>t</i></td><td><i>p</i></td><td>Cohen’s <i>d</i></td><td>ICC</td></tr><tr><td>DCCS</td><td>84</td><td>17</td><td>3.32 (2.35)</td><td>3.89 (2.27)</td><td>−1.51</td><td>.15</td><td>.13</td><td>.88</td></tr><tr><td>Flanker</td><td>82</td><td>17</td><td>4.44 (1.98)</td><td>4.33 (2.33)</td><td>0.23</td><td>.82</td><td>.23</td><td>.75</td></tr><tr><td>List sorting</td><td>66</td><td>14</td><td>9.36 (4.31)</td><td>8.00 (4.47)</td><td>−1.56</td><td>.14</td><td>.31</td><td>.84</td></tr><tr><td>Oral reading</td><td>90</td><td>17</td><td>−3.94 (3.18)</td><td>−3.88 (3.31)</td><td>0.71</td><td>.49</td><td>.03</td><td>.99</td></tr><tr><td>Pattern comparison</td><td>90</td><td>16</td><td>29.53 (13.47)</td><td>35.35 (12.86)</td><td>2.08</td><td>.01</td><td>.44</td><td>.90</td></tr><tr><td>Picture sequence memory</td><td>78</td><td>17</td><td>−1.39 (0.72)</td><td>−1.12 (1.05)</td><td>1.45</td><td>.18</td><td>.46</td><td>.76</td></tr><tr><td>Picture vocabulary</td><td>92</td><td>17</td><td>−2.50 (2.13)</td><td>−3.05 (1.94)</td><td>−1.27</td><td>.22</td><td>.27</td><td>.77</td></tr></table> |
e8b96065e73f38513087ef97baa667776f86787f411be9cefd0588186432766e.png | complex | <table><tr><td></td><td colspan="3">Standard binary method</td><td colspan="3">Augmented binary method</td></tr><tr><td>End point</td><td>Fostamatinib 100 mg response rate</td><td>Placebo response rate</td><td>Difference (95% CI)</td><td>Fostamatinib 100 mg response rate</td><td>Placebo response rate</td><td>Difference (95%CI)</td></tr><tr><td>ACR20</td><td>0.47 (0.42, 0.53)</td><td>0.34 (0.29, 0.39)</td><td>0.13 (0.05,0.21)</td><td>0.53 (0.49, 0.58)</td><td>0.34 (0.29, 0.39)</td><td>0.19 (0.13, 0.26)</td></tr><tr><td>ACR50</td><td>0.23 (0.18, 0.27)</td><td>0.08 (0.05, 0.11)</td><td>0.15 (0.09,0.20)</td><td>0.26 (0.22, 0.30)</td><td>0.13 (0.10, 0.16)</td><td>0.13 (0.08, 0.18)</td></tr><tr><td>ACR70</td><td>0.10 (0.06, 0.13)</td><td>0.02 (0.00, 0.04)</td><td>0.08 (0.04,0.11)</td><td>0.10 (0.09, 0.12)</td><td>0.04 (0.03, 0.05)</td><td>0.06 (0.04, 0.08)</td></tr><tr><td>DAS28 <3.2</td><td>0.26 (0.21, 0.30)</td><td>0.11 (0.07, 0.14)</td><td>0.15 (0.09,0.21)</td><td>0.25 (0.21, 0.28)</td><td>0.12 (0.09, 0.14)</td><td>0.13 (0.08, 0.17)</td></tr><tr><td>DAS28 <2.6</td><td>0.13 (0.09, 0.16)</td><td>0.05 (0.02, 0.07)</td><td>0.08 (0.04,0.12)</td><td>0.12 (0.10, 0.15)</td><td>0.05 (0.04, 0.06)</td><td>0.07 (0.05, 0.10)</td></tr></table> |
33ca277c25e52af909c5a4a43d7662ddfbd0891a6f3745bba4e9450de41000fb.png | simple | <table><tr><td>Outcome: any type of<i>TP53-mutations</i>in a tumor</td><td>HR</td><td>95% CI</td><td><i>p</i>-value</td></tr><tr><td>Having both disruptive<i>TP53-mutations</i>and<i>UGT2B17</i>-deletions</td><td>2.22</td><td>1.30 to 3.80</td><td>0.004</td></tr><tr><td><i>p16</i>-positive tumor</td><td>0.53</td><td>0.29 to 0.99</td><td>0.047</td></tr><tr><td>Stage IV</td><td>2.32</td><td>1.44 to 3.74</td><td>0.001</td></tr><tr><td>Poorly differentiated tumor grade</td><td>1.66</td><td>1.01 to 2.74</td><td>0.047</td></tr></table> |
ab262084f5f38b5a4c7ee08945ab9f0b73d495c349a1b336d2006b9f5f4d4758.png | simple | <table><tr><td></td><td>Accuracy</td><td>Mean Absolute Error</td><td>Area under the ROC Curve</td></tr><tr><td>Logistic Regression</td><td>80.0%</td><td>0.201</td><td>0.854</td></tr><tr><td>Bayesian Network</td><td>96.4%</td><td>0.129</td><td>0.931</td></tr><tr><td>Artificial Neural Network</td><td>96.4%</td><td>0.045</td><td>0.941</td></tr></table> |
5bc677482056f1e8d252f7c5fe19964cd2b7248422a9492895b74a4de49e966d.png | simple | <table><tr><td></td><td>Silica Gels</td><td>Zeolites</td><td>ALPO<sub>S</sub>/SAPO<sub>S</sub></td><td>Composites</td><td>MOFs</td><td>Activated Carbons</td></tr><tr><td>Adsorption heat (kJ/kg)</td><td>160 ÷ 180 *</td><td>50 ÷ 300*</td><td>250 ÷ 300 *</td><td>50 ÷ 250*</td><td>20 ÷ 200 **</td><td>45 ÷ 900 ***</td></tr><tr><td>Typical desorption temperatures [°C]</td><td>50 ÷ 80</td><td>70 ÷ 350</td><td>60 ÷ 90</td><td>60 ÷ 90</td><td>60 ÷ 150</td><td>80 ÷ 200</td></tr><tr><td>Density (kg/m<sup>3</sup>)</td><td>650 ÷ 700</td><td>650 ÷ 900</td><td>800 ÷ 900</td><td>300 ÷ 600</td><td>1000 ÷ 2000</td><td>700 ÷ 750</td></tr><tr><td>Specific heat (kJ/kgK)</td><td>0.8 ÷ 0.9</td><td>0.85 ÷ 0.95</td><td>0.85 ÷ 0.95</td><td>0.95 ÷ 1.05</td><td>0.8 ÷ 1.2</td><td>0.8 ÷ 1.5</td></tr><tr><td>Thermal conductivity (W/mK)</td><td>0.15 ÷ 0.20</td><td>0.15 ÷ 0.25</td><td>0.15 ÷ 0.25</td><td>0.15 ÷ 0.30</td><td>0.10 ÷ 015</td><td>0.15 ÷ 0.75</td></tr><tr><td>Possible refrigerants</td><td>water</td><td>water</td><td>water</td><td>water, methanol, ethanol</td><td>water, methanol, ethanol</td><td>methanol, ethanol, ammonia</td></tr><tr><td>Amount of uptake exchanged in a typical cyle [g/g]</td><td>0.03 ÷ 0.10</td><td>up to 0.2</td><td>up to 0.25</td><td>up to 0.8</td><td>0.16 ÷ 0.40</td><td>015 ÷ 0.60</td></tr></table> |
ed7deffa53670a97d436c9b9ecafe717f5c163e1dd0993f4e2255d8eb1fb2b55.png | complex | <table><tr><td></td><td>Study 1</td><td>Study 2</td></tr><tr><td>Location</td><td>Newcastle, Australia</td><td>Bad Nauheim, Germany</td></tr><tr><td>Aim</td><td>Develop model, Determine spontaneous recanalization rate</td><td>Determine recanalization rates with microbubble + sonothrombolysis enhancement of tPA</td></tr><tr><td>Primary Outcome [method]</td><td>Recanalization [Laser Doppler]</td><td>Recanalization [Laser Doppler]</td></tr><tr><td>Secondary Outcome(s) [method]</td><td>Infarct Volumes [TTC], Mortality, Neurological Deficit scores</td><td>Clot lysis [Inspection of the major branches of the cerebral arterial circulation]</td></tr><tr><td>Survival post-embolism</td><td>24 h</td><td>2 h</td></tr><tr><td>Treatment groups (n)</td><td>No treatment (n = 7)</td><td>Saline (n = 10), tPA (n = 10), tPA + Ultrasound + BR38 microbubbles (n = 10)</td></tr><tr><td rowspan="2">Laser Doppler Monitoring</td><td>Continuous</td><td>Discontinuous</td></tr><tr><td><i>To 4 h post-embolism</i></td><td><i>Pre-embolism, Post-embolism, Pre-treatment, Post-treatment</i></td></tr></table> |
455d9698c1b105b8907dc8860a7d7e1c5256e95f41252812097551853091d4df.png | simple | <table><tr><td>RASgrf1</td><td>primers</td><td>Length (bp)</td></tr><tr><td>Segment 1</td><td>Forward TTTGTGAGGAAAGATGGTGTTGReverse AAACCATAAAAACCTTCACATAACTAC</td><td>349</td></tr><tr><td>Segment 2</td><td>Forward GTAGAGAAGAGGAAAATAAGGAGGReverse CGAAAACCCCTAAAAATATTACAC</td><td>347</td></tr></table> |
84b99c7f001f7bf7709c94c05c85400d21b3d2b7a8838e60445afc79f8bbf26f.png | simple | <table><tr><td>#</td><td>Code</td><td>Site Name</td><td>Country</td><td>N</td><td>Latitude</td><td>Longitude</td></tr><tr><td>1</td><td>GRO</td><td>Grosbeak Lake</td><td>Canada</td><td>11</td><td>59.792</td><td>-111.996</td></tr><tr><td>2</td><td>FOR</td><td>Forgotten Pass Lake</td><td>Canada</td><td>2</td><td>59.58</td><td>-111.451</td></tr><tr><td>3</td><td>HAY</td><td>Hay Camp Lake</td><td>Canada</td><td>3</td><td>59.541</td><td>-111.465</td></tr><tr><td>4</td><td>TUR</td><td>Estany d'en Turies</td><td>Spain</td><td>7</td><td>42.243</td><td>3.103</td></tr><tr><td>5</td><td>CHI</td><td>Salada de Chiprana</td><td>Spain</td><td>8</td><td>41.239</td><td>-0.182</td></tr><tr><td>6</td><td>ERA</td><td>Laguna de las Eras</td><td>Spain</td><td>10</td><td>41.202</td><td>-4.582</td></tr><tr><td>7</td><td>SA2</td><td>Balsa de Santed II</td><td>Spain</td><td>10</td><td>41.016</td><td>-1.542</td></tr><tr><td>8</td><td>GAL</td><td>Laguna de Gallocanta</td><td>Spain</td><td>5</td><td>40.974</td><td>-1.508</td></tr><tr><td>9</td><td>TON</td><td>Torreblanca Marsh, Poza Norte</td><td>Spain</td><td>4</td><td>40.148</td><td>0.17</td></tr><tr><td>10</td><td>TOS</td><td>Torreblanca Marsh, Poza Sur</td><td>Spain</td><td>12</td><td>40.146</td><td>0.168</td></tr><tr><td>11</td><td>MAN</td><td>Laguna de Manjavacas</td><td>Spain</td><td>9</td><td>39.416</td><td>-2.866</td></tr><tr><td>12</td><td><i>TIA</i></td><td>Tianjin</td><td>China</td><td>3</td><td>39.158</td><td>117.176</td></tr><tr><td>13</td><td>SAL</td><td>Laguna del Salobrejo</td><td>Spain</td><td>5</td><td>38.914</td><td>-1.469</td></tr><tr><td>14</td><td>PET</td><td>Laguna de Pétrola</td><td>Spain</td><td>9</td><td>38.84</td><td>-1.566</td></tr><tr><td>15</td><td>MOJ</td><td>Laguna de Mojón Blanco</td><td>Spain</td><td>2</td><td>38.798</td><td>-1.432</td></tr><tr><td>16</td><td>SLD</td><td>Laguna del Saladar</td><td>Spain</td><td>4</td><td>38.789</td><td>-1.419</td></tr><tr><td>17</td><td>HOY</td><td>Laguna de Hoya Rasa</td><td>Spain</td><td>2</td><td>38.785</td><td>-1.428</td></tr><tr><td>18</td><td>CAS</td><td>Laguna de Casa Nueva</td><td>Spain</td><td>2</td><td>38.776</td><td>-1.433</td></tr><tr><td>19</td><td>ATA</td><td>Laguna de Atalaya de los Ojicos</td><td>Spain</td><td>3</td><td>38.773</td><td>-1.43</td></tr><tr><td>20</td><td>CLO</td><td>Clot de Galvany</td><td>Spain</td><td>2</td><td>38.246</td><td>-0.546</td></tr><tr><td>21</td><td>FUE</td><td>Laguna de Fuente de Piedra</td><td>Spain</td><td>2</td><td>37.109</td><td>-4.767</td></tr><tr><td>22</td><td>CAP</td><td>Laguna de Capacete</td><td>Spain</td><td>5</td><td>37.016</td><td>-4.842</td></tr><tr><td>23</td><td><i>EEL</i>†</td><td>Eel Pond</td><td>Japan</td><td>4</td><td>34.717</td><td>136.533</td></tr><tr><td>24</td><td><i>ATL</i></td><td>Atlit coast</td><td>Israel</td><td>1</td><td>32.703</td><td>34.94</td></tr><tr><td>25</td><td><i>SAP</i></td><td>Sapelo</td><td>USA</td><td>1</td><td>31.5</td><td>-81.219</td></tr><tr><td>26</td><td><i>EIL</i></td><td>Eilat</td><td>Israel</td><td>1</td><td>29.56</td><td>34.967</td></tr><tr><td>27</td><td><i>MEA</i></td><td>Meagher Pond</td><td>USA (Caribbean)</td><td>1</td><td>19.295</td><td>-81.232</td></tr><tr><td>28</td><td>WAN</td><td>Lake Wannamal</td><td>Australia</td><td>2</td><td>-31.109</td><td>116.049</td></tr><tr><td>29</td><td>PEA</td><td>Pearse's Lake</td><td>Australia</td><td>3</td><td>-31.629</td><td>116.914</td></tr><tr><td>30</td><td>YEN</td><td>Yenyenning Lakes</td><td>Australia</td><td>1</td><td>-32.235</td><td>117.233</td></tr><tr><td>31</td><td>HOT</td><td>Hotham River</td><td>Australia</td><td>1</td><td>-32.64</td><td>116.977</td></tr><tr><td>32</td><td>BUS</td><td>Bushy Swamp</td><td>Australia</td><td>2</td><td>-33.541</td><td>117.27</td></tr><tr><td>33</td><td>DUN</td><td>Dunn's Swamp</td><td>Australia</td><td>1</td><td>-33.924</td><td>120.155</td></tr><tr><td>34</td><td>BUL</td><td>Lake Bulla</td><td>Australia</td><td>1</td><td>-34.755</td><td>142.361</td></tr><tr><td>35</td><td>COL</td><td>Lake Colongulac</td><td>Australia</td><td>2</td><td>-38.173</td><td>143.163</td></tr><tr><td>36</td><td><i>TOH</i></td><td>Tower Hill Lake</td><td>Australia</td><td>5</td><td>-38.325</td><td>142.368</td></tr></table> |
3a06a0b2b206b23d4115155d4f6d4c53c3c2fa4bce9130797d7859c83f57dc48.png | simple | <table><tr><td>Protein</td><td>Construct OPPF_</td><td>Yield/(mg/l)</td><td>Number of 96 well plates</td><td>Structure</td></tr><tr><td>ZHX1</td><td>1612</td><td>4.5</td><td>16</td><td></td></tr><tr><td></td><td>1613</td><td>2.1</td><td>10</td><td></td></tr><tr><td></td><td>1615</td><td>2.3</td><td>14</td><td></td></tr><tr><td></td><td>1632</td><td>1.8</td><td>12</td><td></td></tr><tr><td></td><td>1633</td><td>2.3</td><td>6</td><td></td></tr><tr><td></td><td>1635</td><td>3.5</td><td>17</td><td></td></tr><tr><td></td><td>1636</td><td>5.9</td><td>11</td><td></td></tr><tr><td></td><td>2264</td><td>4.1</td><td>12</td><td></td></tr><tr><td></td><td>2265</td><td>3.9</td><td>32</td><td>Yes</td></tr><tr><td>ZHX2</td><td>2268</td><td>11.5</td><td>25</td><td></td></tr><tr><td></td><td>2273</td><td>5.0</td><td>14</td><td>Yes</td></tr><tr><td>ZHX3</td><td>2274</td><td>2.5</td><td>8</td><td></td></tr><tr><td></td><td>2279</td><td>6.3</td><td>8</td><td></td></tr></table> |
dfad11088d7dd69fa96d5676e7a033af86168f568c68fe90304c7449a181907c.png | complex | <table><tr><td rowspan="2"></td><td colspan="3">Number of</td><td colspan="2">BMI</td><td rowspan="2">Time of smoking</td><td rowspan="2">Average number of smoked cigarettes</td><td rowspan="2">Passive smoking at work</td><td rowspan="2">Passive smoking at home</td></tr><tr><td>Subjects</td><td>Women</td><td>Men</td><td>Women</td><td>Men</td></tr><tr><td colspan="10">Urine</td></tr><tr><td> Smokers</td><td>26</td><td>16</td><td>10</td><td>22.2</td><td>24.9</td><td>In the evening</td><td>6–10</td><td>Yes</td><td>Yes</td></tr><tr><td> Passive smokers</td><td>25</td><td>13</td><td>12</td><td>23.01</td><td>22.32</td><td>n/a</td><td>n/a</td><td>Yes</td><td>Yes</td></tr><tr><td> Control group</td><td>16</td><td>10</td><td>6</td><td>20.7</td><td>22.2</td><td>n/a</td><td>n/a</td><td>No</td><td>No</td></tr><tr><td colspan="10">Saliva</td></tr><tr><td> Smokers</td><td>11</td><td>8</td><td>3</td><td>22.7</td><td>24.2</td><td>In the evening</td><td>1–5</td><td>No</td><td>Yes</td></tr><tr><td> Passive smokers</td><td>16</td><td>11</td><td>5</td><td>22.4</td><td>23.1</td><td>n/a</td><td>n/a</td><td>No</td><td>Yes</td></tr><tr><td> Control group</td><td>10</td><td>7</td><td>3</td><td>21.8</td><td>23.4</td><td>n/a</td><td>n/a</td><td>No</td><td>No</td></tr></table> |
42b484d440f082fd844ae8e6a81c6f80b39fd6a5bd5624c63d00abc3f09bc377.png | complex | <table><tr><td></td><td>Delirium (<i>n</i> = 35)</td><td>No delirium (<i>n</i> = 15)</td><td>Differences (<i>p</i> value)</td></tr><tr><td>Age in years, mean (SD)</td><td>73 (9.9)</td><td>67 (10)</td><td>0.03</td></tr><tr><td>Male, <i>n</i> (%)</td><td>23 (66)</td><td>13 (87)</td><td>0.12</td></tr><tr><td colspan="4">Admission type:</td></tr><tr><td> Surgical (%)</td><td>8 (23)</td><td>3 (20)</td><td></td></tr><tr><td> Medical (%)</td><td>26 (74)</td><td>10 (67)</td><td>0.35</td></tr><tr><td> Neurotrauma (%)</td><td>1 (3)</td><td>2 (13)</td><td></td></tr><tr><td>APACHE-II score (SD)</td><td>26 (7)</td><td>28 (9)</td><td>0.42</td></tr><tr><td>Sepsis (patients), <i>n</i> (%)</td><td>16 (46)</td><td>3 (20)</td><td>0.08</td></tr><tr><td>PRE-DELIRIC score (mean, SD)</td><td>78 (18)</td><td>74 (19)</td><td>0.45</td></tr><tr><td>History of cognitive disorder, <i>n</i> (%)</td><td>4 (11)</td><td>1 (7)</td><td>0.52</td></tr><tr><td>Diabetes mellitus, <i>n</i> (%)</td><td>5 (14)</td><td>1 (7)</td><td>0.41</td></tr><tr><td>COPD, <i>n</i> (%)</td><td>1 (3)</td><td>2 (13)</td><td>0.21</td></tr><tr><td>Acute kidney injury, <i>n</i> (%)</td><td>12 (34)</td><td>3 (20)</td><td>0.25</td></tr><tr><td>Cardiovascular disease, <i>n</i> (%)</td><td>1 (3)</td><td>1 (7)</td><td>0.51</td></tr><tr><td>Use of steroids, <i>n</i> (%)</td><td>18 (51)</td><td>8 (53)</td><td>0.57</td></tr><tr><td>Study arm (DLA), <i>n</i> (%)</td><td>19 (54)</td><td>8 (53)</td><td>0.6</td></tr><tr><td>Intubation, <i>n</i> (%)</td><td>31(89)</td><td>14(93)</td><td>0.52</td></tr><tr><td>Hours of mechanical ventilation, median (IQR)</td><td>158 (96–281)</td><td>194 (116–383)</td><td>0.58</td></tr><tr><td>LOS-ICU in days, median (IQR)</td><td>12 (10–19)</td><td>15 (9–24)</td><td>0.45</td></tr><tr><td>LOS-hospital in days, median (IQR)</td><td>30 (17–42)</td><td>35 (19–50)</td><td>0.79</td></tr><tr><td>Hospital mortality, <i>n</i> (%)</td><td>12 (34)</td><td>3 (20)</td><td>0.25</td></tr></table> |
670e2602239728d562c62112822d0bdfc91994a04173e4dda10092c9005b9335.png | complex | <table><tr><td>Clinicopathologic parameter</td><td>Total case (n = 134)</td><td>High level of HSF-1 in tumor (%)</td><td>P</td><td>High level of HSF-1 in stromal (%)</td><td>P</td></tr><tr><td colspan="6">Age (years)</td></tr><tr><td> ≤61</td><td>67</td><td>37 (55.2)</td><td rowspan="2">0.727</td><td>36 (53.7)</td><td rowspan="2">0.486</td></tr><tr><td> >61</td><td>67</td><td>39 (58.2)</td><td>40 (59.7)</td></tr><tr><td colspan="6">Gender</td></tr><tr><td> Female</td><td>26</td><td>11 (42.3)</td><td rowspan="2">0.099</td><td>10 (38.5)</td><td rowspan="2">0.036*</td></tr><tr><td> Male</td><td>108</td><td>65 (60.2)</td><td>66 (61.1)</td></tr><tr><td colspan="6">Degree of differentiation</td></tr><tr><td> G1</td><td>42</td><td>18 (42.9)</td><td rowspan="3">0.082</td><td>17 (40.5)</td><td rowspan="3">0.021*</td></tr><tr><td> G2</td><td>57</td><td>37 (64.9)</td><td>39 (68.4)</td></tr><tr><td> G3</td><td>35</td><td>21 (60.0)</td><td>20 (57.1)</td></tr><tr><td colspan="6">T status</td></tr><tr><td> T1–2</td><td>48</td><td>15 (31.2)</td><td rowspan="2"><0.001*</td><td>15 (31.2)</td><td rowspan="2"><0.001*</td></tr><tr><td> T3–4</td><td>86</td><td>61 (70.9)</td><td>61 (70.9)</td></tr><tr><td colspan="6">N status</td></tr><tr><td> N0</td><td>65</td><td>29 (44.6)</td><td rowspan="2">0.006*</td><td>28 (43.1)</td><td rowspan="2">0.002*</td></tr><tr><td> N1</td><td>69</td><td>47 (68.1)</td><td>48 (69.6)</td></tr><tr><td colspan="6">M status</td></tr><tr><td> M0</td><td>128</td><td>73 (57.0)</td><td rowspan="2">1.000</td><td>72 (56.2)</td><td rowspan="2">0.935</td></tr><tr><td> M1</td><td>6</td><td>3 (50.0)</td><td>4 (66.7)</td></tr><tr><td colspan="6">Clinical stage</td></tr><tr><td> I–II</td><td>72</td><td>32 (44.4)</td><td rowspan="2">0.002*</td><td>33 (45.8)</td><td rowspan="2">0.006*</td></tr><tr><td> III–IV</td><td>62</td><td>44 (71.0)</td><td>43 (69.4)</td></tr></table> |
8763ffdb39b61fcc9983e66256701389003da4df3728b855f7dfd40015da6b01.png | simple | <table><tr><td>Sr. No. </td><td>Formulation </td><td>Droplet size (nm)</td><td>Zeta potential (mv)</td></tr><tr><td>1 </td><td>AILP – A </td><td>246</td><td>-0.232</td></tr><tr><td>2 </td><td>AILP – B </td><td>213</td><td>-0.114</td></tr><tr><td>3 </td><td>AILP – C </td><td>200</td><td>-0.535</td></tr><tr><td>4 </td><td>AILP – D </td><td>144</td><td>-0.596</td></tr><tr><td>5 </td><td>AILP – E </td><td>136</td><td>-0.185</td></tr></table> |
5742df014711e27ac2e70247eeb5c29d41bc2b8bd96873aeb2c17ca7d8296d6c.png | simple | <table><tr><td>Combination Label</td><td>Transfer Function (Hidden Neuron)</td><td>Transfer Function (Output Neuron)</td><td>No. of Output Neurons</td></tr><tr><td>CA</td><td>logsig</td><td>logsig</td><td>4</td></tr><tr><td>CB</td><td>tansig</td><td>logsig</td><td>4</td></tr><tr><td>CC</td><td>logsig</td><td>logsig</td><td>2</td></tr><tr><td>CD</td><td>tansig</td><td>logsig</td><td>2</td></tr><tr><td>CE</td><td>logsig</td><td>purelin</td><td>1</td></tr><tr><td>CF</td><td>tansig</td><td>purelin</td><td>1</td></tr></table> |
a7ea781f088d5f2974bc7c0b5684da7425bc5e2cb7aebd77b742fe0474a9ab86.png | complex | <table><tr><td>Tracking method – mechanism</td><td>Disadvantages</td><td>Advantages</td></tr><tr><td rowspan="4">GFP, luciferase – DNA transfer can be mediated virally (transduction), via liposomes (lipofection), or by electrical parameters (electroporation/transfection)</td><td>- Genetic manipulation of cells may alter their function</td><td>- Human ASCs with GFP or luciferase resume proliferation normally</td></tr><tr><td>- Since they are cytosolic in location; the vector (mRNA/DNA) and/or the protein (GFP) could be transmitted to host cells via fusion elements and/or microvesicle secretion, resulting in contamination. Hence, there is concern for false positivity and their detection may not equate to viability of donor cells</td><td>- Detection is sensitive to <i>in vivo</i> non-invasive bioluminescence imaging</td></tr><tr><td>- Technique requires serial passages, not suitable for use with fresh uncultured cells</td><td></td></tr><tr><td>- Many mammalian tissues have endogenous fluorescence</td><td></td></tr><tr><td rowspan="4">BrdU – this nuclear marker is a thymidine analog that replaces (3H) thymidine and can penetrate cell membranes to incorporate into newly synthesized DNA strands of actively proliferating cells</td><td>- Optimal labeling requires longer incubation time</td><td rowspan="4">- BrdU labeling has no effects on the ASC differentiation/proliferation and is not cytotoxic</td></tr><tr><td>- Not suitable for non-invasive methods of detection</td></tr><tr><td>- Does not indicate viability</td></tr><tr><td>- Cells lose BrdU rapidly with serial passages</td></tr><tr><td rowspan="3">Lipophilic dyes (DiI, DiR) –long-chain carbocyanine dyes with long aliphatic tails that incorporate into the lipid regions of the cell membranes</td><td>- Rapidly contaminates neighboring cells by macrophage-mediated phagocytosis, exchange of membrane microdomains, microvesicle and/or exosome transfer</td><td rowspan="3">- Easy technique for labeling and identification of cells</td></tr><tr><td>- May be cytotoxic to cells</td></tr><tr><td>- The dye fades with serial passages</td></tr><tr><td rowspan="4">Amine reactive probes (CFSE) – these diffuse into cells and react with cytosolic amine-containing residues to form dye–protein adducts that are retained</td><td>- The dye is toxic to ASCs</td><td rowspan="4">- Good staining efficiency</td></tr><tr><td>- Not suitable for <i>in vivo</i> non-invasive imaging</td></tr><tr><td>- Does not correlate with viability</td></tr><tr><td>- Contamination of neighboring cells can occur via macrophage-mediated phagocytosis, microvesicle and/or exosome transfer</td></tr><tr><td rowspan="3">Nanoparticles – small crystals made up of inorganic molecules; for example, iron oxide, cadmium</td><td>- Can be toxic to cells in high concentration and detection is difficult with low concentrations</td><td>- Photostable, remain resistant for long periods of time</td></tr><tr><td>- Contamination of neighboring cells can occur via phagocytosis, microvesicles and/or exosome transfer</td><td rowspan="2">- Can be used for <i>in vivo</i> non-invasive imaging</td></tr><tr><td>- Does not correlate with viability</td></tr><tr><td rowspan="3">Real-time PCR for endogenous retroviral sequence (ERV-3) – the gene is present as a single copy in the human genome and so can be used to detect the presence of transplanted human cells in animal models</td><td>- Not suitable for non-invasive methods of detection</td><td>- Gives a quantitative estimate of number of cells</td></tr><tr><td>- False positives can occur by macrophage-mediated phagocytosis but this is very low</td><td>- Very sensitive and specific</td></tr><tr><td></td><td>- The gene is already present in the human cells, so there is no need to stain the cells</td></tr><tr><td rowspan="3">FISH detection of human-specific cell surface markers or Alu sequences</td><td>- Alu sequences occur in large numbers in the primate genome, which makes higher likelihood of a false positive detection by transmission to host cells/macrophages via microvesicles/exosomes</td><td>- The gene is already present in the human cells, so there is no need to stain the cells</td></tr><tr><td>- Not suitable for non-invasive methods of detection</td><td></td></tr><tr><td>- Does not correlate with viability</td><td></td></tr></table> |
2cf4cba38a41479e112075d5dd90536dcd1a31d6efde287909af87311d9cf71b.png | simple | <table><tr><td>Features</td><td><i>Bt</i> X022</td><td><i>Bt</i> 4.0718</td></tr><tr><td>Chromosome size</td><td>5,460,989 bp</td><td>5,641,982 bp</td></tr><tr><td>Number of plasmids</td><td>7</td><td>6</td></tr><tr><td>Predicted CDSs</td><td>5888</td><td>6797</td></tr><tr><td>Hypothetical genes</td><td>1592</td><td>1826</td></tr><tr><td>ncRNAs</td><td>148</td><td>94</td></tr><tr><td>Predicted insecticidal genes</td><td>4</td><td>6</td></tr></table> |
7bed062f75fd6fc06628b7b7dede32e6249a4804cea1587c1e6ebdf57014ad50.png | complex | <table><tr><td rowspan="3">Signal + harmonic</td><td colspan="2">Frequency estimation (Hz)</td><td colspan="2">Error (Hz)</td></tr><tr><td>Mean (μ)</td><td>Standard deviation (σ)</td><td>Mean (μ)</td><td>Standard deviation (σ)</td></tr><tr><td>2<sup>nd</sup></td><td>60.0000</td><td>0.0000</td><td>0.0000</td><td>0.0000</td></tr><tr><td>3<sup>rd</sup></td><td>60.0000</td><td>0.0000</td><td>0.0000</td><td>0.0000</td></tr><tr><td>3<sup>rd</sup> + 5<sup>th</sup></td><td>60.0000</td><td>0.0000</td><td>0.0000</td><td>0.0000</td></tr></table> |
b930856b396cb90b2282583b095120d03e03e749fbf4c4ec0b87a1017b88cd6c.png | complex | <table><tr><td colspan="2">Clinical observations and epidemiological arguments </td></tr><tr><td>(I)</td><td>The prevalence rates of OCS in schizophrenia increased after market approval of SGAs such as clozapine. </td></tr><tr><td>(II)</td><td>The comorbidity rates in later stages of schizophrenia are higher than during the ARMS or at first manifestation of psychosis.</td></tr><tr><td>(III)</td><td>In parallel to antipsychotic treatment OCS manifest <i>de novo </i>or show a marked aggravation.</td></tr><tr><td>(IV)</td><td>High prevalence rates of OCS are observed during CLZ treatment.</td></tr><tr><td>(V)</td><td>Schizophrenia patients with SGA-induced OCS markedly contribute to the entire sample of comorbid patients.</td></tr><tr><td colspan="2">Evidence derived from pharmacological considerations</td></tr><tr><td>(I)</td><td>Pharmacodynamic properties modulate the risk for OCS: marked difference between samples treated with first generation antipsychotics or mainly dopaminergic SGAs (such as aripiprazole or amisulpride) compared to CLZ.</td></tr><tr><td>(II)</td><td>OCS manifest as an unfavourable drug effect <i>de novo</i> during treatment with potent antiserotonergic SGAs such as CLZ.</td></tr><tr><td>(III)</td><td>Indicators of a dose-effect relation: the severity of OCS is positively correlated with duration, dosage, and serum levels of CLZ treatment. </td></tr><tr><td>(IV)</td><td>OCS severity persists over time in patients under stable CLZ treatment.</td></tr><tr><td>(V)</td><td>The severity of OCS improves after reduction of CLZ dosage to minimally sufficient levels (due to augmentation or combination).</td></tr></table> |
af99d9735c0782a213ba1239e40faac053237b08008bf022335f90aa729045c4.png | simple | <table><tr><td>Classification of <i>Theileria</i> gene pairs<sup>a</sup></td><td><i>Theileria</i> consecutive gene pairs with orthologs in <i>P. falciparum</i><sup>c</sup></td><td>Pairs in <i>Theileria</i> with conserved synteny in <i>Plasmodium</i><sup>b</sup></td><td>Percent conserved pairs<sup>d</sup></td></tr><tr><td>Opposite strand</td><td>940</td><td>64</td><td>22.66</td></tr><tr><td>Opposite strand Overlap</td><td>182</td><td>64</td><td>35.16</td></tr><tr><td>Same-strand</td><td>805</td><td>125</td><td>15.53</td></tr></table> |
3b5f90fe40a0bc9e8897e770b374f449e90bf720023594cc39d9da2923ea9354.png | complex | <table><tr><td>Focus groups</td><td colspan="2">Age category</td><td colspan="2">Gender</td><td colspan="2">Relationship</td></tr><tr><td colspan="7">More homogeneous groups</td></tr><tr><td></td><td>< 50 yrs</td><td>50 + yrs</td><td>Female</td><td>Male</td><td>Spouse</td><td>Other</td></tr><tr><td>Group A</td><td rowspan="3">2</td><td rowspan="3">5</td><td rowspan="3">5</td><td rowspan="3">2</td><td rowspan="3">6</td><td rowspan="3">1</td></tr><tr><td>Asian Indian = 5</td></tr><tr><td>Asian Pakistani = 2</td></tr><tr><td>Group B</td><td rowspan="2">1</td><td rowspan="2">6</td><td rowspan="2">4</td><td rowspan="2">3</td><td rowspan="2">2</td><td rowspan="2">5</td></tr><tr><td>Asian Indian = 7</td></tr><tr><td>Group C</td><td rowspan="2">0</td><td rowspan="2">5</td><td rowspan="2">2</td><td rowspan="2">3</td><td rowspan="2">4</td><td rowspan="2">1</td></tr><tr><td>White British = 5</td></tr><tr><td>Group D</td><td rowspan="2">0</td><td rowspan="2">3</td><td rowspan="2">3</td><td rowspan="2">0</td><td rowspan="2">3</td><td rowspan="2">0</td></tr><tr><td>White British = 3</td></tr><tr><td>Group E</td><td rowspan="3">3</td><td rowspan="3">4</td><td rowspan="3">5</td><td rowspan="3">2</td><td rowspan="3">2</td><td rowspan="3">5</td></tr><tr><td>Black Caribbean = 3</td></tr><tr><td>Black African = 4</td></tr><tr><td colspan="7">More heterogeneous groups</td></tr><tr><td>Group F</td><td rowspan="5">0</td><td rowspan="5">5</td><td rowspan="5">3</td><td rowspan="5">2</td><td rowspan="5">4</td><td rowspan="5">1</td></tr><tr><td>Asian Indian = 1</td></tr><tr><td>Asian Pakistani = 2</td></tr><tr><td>Black Caribbean = 1</td></tr><tr><td>White British = 1</td></tr><tr><td>Group G</td><td rowspan="5">2</td><td rowspan="5">5</td><td rowspan="5">7</td><td rowspan="5">0</td><td rowspan="5">7</td><td rowspan="5">0</td></tr><tr><td>Asian Indian = 4</td></tr><tr><td>Black African = 1</td></tr><tr><td>White British = 1</td></tr><tr><td>Black Caribbean = 1</td></tr><tr><td>Total = 41</td><td>8</td><td>33</td><td>29</td><td>12</td><td>28</td><td>13</td></tr></table> |
5f56f382919102d075ce43188d9729263673ae52c98bae98aa7ab0826abebd49.png | simple | <table><tr><td> </td><td>Pregnant</td><td>Not pregnant</td></tr><tr><td><i>Percent of total cycles</i></td><td>36.7</td><td>63.3</td></tr><tr><td><i>Age (years)</i></td><td>36.5 ± 5.3</td><td>37.0 ± 4.6</td></tr><tr><td><i>Embryos biopsied (n)</i></td><td>7.7 ± 3.7</td><td>7.0 ± 3.8</td></tr><tr><td><i> ≤ 6 n (%)</i></td><td>20 (50.0)</td><td>35 (50.7)</td></tr><tr><td><i> ≥ 7 n (%)</i></td><td>20 (50.0)</td><td>34 (49.3)</td></tr><tr><td><i>Euploid embryos (n)</i><sup><i>1</i></sup></td><td>4.5 ± 2.4</td><td>3.3 ± 2.2</td></tr><tr><td><i> ≤ 3 n (%)</i></td><td>16 (40.0)</td><td>42 (60.9)</td></tr><tr><td><i>% pregnant</i></td><td>27.6</td><td> </td></tr><tr><td><i> ≥ 4 n (%)</i></td><td>24 (60.0)</td><td>27 (39.1)</td></tr><tr><td><i>% pregnant</i></td><td>47.1</td><td> </td></tr><tr><td><i>Embryos transferred (n)</i></td><td>2.1 ± 0.7</td><td>1.6 ± 0.8</td></tr><tr><td><i>≥ 2 euploid embryos available</i><sup><i>2</i></sup></td><td> </td><td> </td></tr><tr><td><i> n (%) pregnant ET x 1</i></td><td>4/35 (11.4)</td><td> </td></tr><tr><td><i> n (%) pregnant ET x 2</i></td><td>36/74 (48.6)</td><td> </td></tr></table> |
a122111a9f9f15d0a3c81c0896684f11f5f88fbeac3780d63e743231b5833d8d.png | simple | <table><tr><td>Factor</td><td>Numerator df</td><td>Denominator df</td><td><i>F</i></td><td><i>P</i></td></tr><tr><td>Support level</td><td>4</td><td>528</td><td>5.36</td><td>0.0003</td></tr><tr><td>Stimulus intensity</td><td>9</td><td>528</td><td>211.62</td><td><0.0001</td></tr><tr><td>Background EMG</td><td>1</td><td>528</td><td>0.88</td><td>0.3497</td></tr><tr><td>Support × Stimulus</td><td>36</td><td>528</td><td>0.83</td><td>0.7505</td></tr><tr><td>Support × Background</td><td>4</td><td>528</td><td>2.34</td><td>0.0542</td></tr><tr><td>Stimulus × Background</td><td>9</td><td>528</td><td>1.41</td><td>0.1805</td></tr><tr><td>Support × Stimulus × Background</td><td>36</td><td>528</td><td>1.10</td><td>0.3248</td></tr></table> |
5a10d1d41bb9c0c0f6d1e7634e559acb1a7d767aac315df2070a4b2b1ed0d0e5.png | complex | <table><tr><td></td><td colspan="7">Distances</td><td></td></tr><tr><td> Classifiers</td><td> 1</td><td> 2</td><td> 3</td><td> 4</td><td> 5</td><td> 6</td><td> 7</td><td> Avg.</td></tr><tr><td rowspan="3">NB</td><td> 68.57</td><td> 69.52</td><td> 72.38</td><td> 75.24</td><td> 75.24</td><td> 72.38</td><td> 70.48</td><td> 71.97</td></tr><tr><td> 75.24</td><td> 83.81</td><td> 81.90</td><td> 83.81</td><td> 85.71</td><td> 86.67</td><td> 86.67</td><td> 83.40</td></tr><tr><td> 67.62</td><td> 73.33</td><td> 72.38</td><td> 73.33</td><td> 74.29</td><td> 74.29</td><td> 75.24</td><td> 72.93</td></tr><tr><td rowspan="3"> LMT</td><td> 75.24</td><td> 78.10</td><td> 76.19</td><td> 77.14</td><td> 77.14</td><td> 80.00</td><td> 82.86</td><td> 78.09</td></tr><tr><td> 80.00</td><td> 82.86</td><td> 80.00</td><td> 83.81</td><td> 86.67</td><td> 86.67</td><td> 82.86</td><td> 83.27</td></tr><tr><td> 70.48</td><td> 80.95</td><td> 78.10</td><td> 81.90</td><td> 76.19</td><td> 79.05</td><td> 80.95</td><td> 78.23</td></tr><tr><td rowspan="3">RT</td><td> 74.29</td><td> 63.81</td><td> 75.24</td><td> 74.29</td><td> 78.10</td><td> 71.43</td><td> 71.43</td><td> 72.66</td></tr><tr><td> 68.57</td><td> 76.19</td><td> 76.19</td><td> 80.95</td><td> 71.43</td><td> 71.43</td><td> 76.19</td><td> 74.42</td></tr><tr><td> 63.81</td><td> 65.71</td><td> 74.29</td><td> 64.76</td><td> 71.43</td><td> 77.14</td><td> 62.86</td><td> 68.57</td></tr><tr><td rowspan="3"> RF</td><td> 71.43</td><td> 74.29</td><td> 83.81</td><td> 84.76</td><td> 82.86</td><td> 80.00</td><td> 76.19</td><td> 79.05</td></tr><tr><td> 83.81</td><td> 87.62</td><td> 81.90</td><td> 88.57</td><td> 86.67</td><td> 90.48</td><td> 83.81</td><td> 86.12</td></tr><tr><td> 77.14</td><td> 81.90</td><td> 73.33</td><td> 82.86</td><td> 78.10</td><td> 82.86</td><td> 82.86</td><td> 79.86</td></tr><tr><td rowspan="3"> SVM</td><td>80.00</td><td>84.76</td><td>87.62</td><td>89.52</td><td>91.43</td><td>90.48</td><td>92.38</td><td>88.03</td></tr><tr><td>89.52</td><td>90.48</td><td>94.29</td><td>94.29</td><td>95.24</td><td>96.19</td><td>95.24</td><td>93.60</td></tr><tr><td>85.71</td><td>89.52</td><td>90.48</td><td>89.52</td><td>90.48</td><td>90.48</td><td>91.43</td><td>89.66</td></tr></table> |
2a45271ba6157d514bb86f55dd7c9667ef4b5b958da024534410fc30e9bc472c.png | complex | <table><tr><td> </td><td colspan="7">TIMP-1 (ng/mL)</td></tr><tr><td rowspan="6">MMP-13 (ng/mL)</td><td> </td><td>12.18</td><td>20.09</td><td>33.12</td><td>54.60</td><td>90.02</td><td>148.41</td></tr><tr><td>33.12</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td>Referencepoint</td></tr><tr><td>54.60</td><td>4.96 [0.27; 9.64] <i>p</i> = 0.038</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td></tr><tr><td>90.02</td><td>4.30 [0.021; 8.59] <i>p</i> = 0.049</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td></tr><tr><td>148.41</td><td>N/A</td><td>N/A</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td><td><i>p</i> > 0.05</td></tr><tr><td>244.69</td><td>N/A</td><td>N/A</td><td><i>p</i> > 0.05</td><td>3.93 [0.084; 7.79] <i>p</i> = 0.045</td><td>4.60 [0.69; 8.51] <i>p</i> = 0.022</td><td>4.43 [0.29; 8.58] <i>p</i> = 0.037</td></tr></table> |
98e0d219a7869b31eb898a5cae8d7cc9c186c67b263e6e15baf82523db401878.png | simple | <table><tr><td>Rank</td><td>Name and cell line</td><td>Mean </td><td>N</td><td>Enrichment</td><td>P</td><td>Specificity</td></tr><tr><td>12</td><td>Estradiol-ssMCF7</td><td>0.700</td><td>2</td><td>0.989</td><td>0.00016</td><td>0.0000</td></tr><tr><td>31</td><td>Estradiol-HL60</td><td>0.303</td><td>8</td><td>0.590</td><td>0.00335</td><td>0.1585</td></tr><tr><td>3091</td><td>Estradiol-MCF7</td><td>0.222</td><td>19</td><td>0.485</td><td>Null</td><td>Null</td></tr><tr><td>3580</td><td>Estradiol-PC3</td><td>-0.040</td><td>8</td><td>0.223</td><td>Null</td><td>Null</td></tr></table> |
eb866f29a40efdbbc30b1d33128fbe53fa606a0bcb9682019e7fc8a7ed5334bd.png | complex | <table><tr><td rowspan="2">Walls</td><td rowspan="2">Moduli identified (MPa)</td><td colspan="2">Measurements</td><td colspan="2">Model</td></tr><tr><td>f<sub>1</sub> (Hz)</td><td>f<sub>2</sub> (Hz)</td><td>f<sub>1</sub> (Hz)</td><td>f<sub>2</sub> (Hz)</td></tr><tr><td>Wall A</td><td>104</td><td>12.25 ± 0.05</td><td>16.25 ± 0.12</td><td>12.25</td><td>16.48</td></tr><tr><td>Wall B</td><td>98</td><td>11.87 ± 0.08</td><td>16.20 ± 0.09</td><td>11.87</td><td>15.97</td></tr><tr><td>Wall C</td><td>90</td><td>11.38 ± 0.10</td><td>15.38 ± 0.22</td><td>11.38</td><td>15.31</td></tr></table> |
4b1c5b0f677484e511316f87bb392bbf4550ff424b564f71ec50e5c0d80391f7.png | simple | <table><tr><td>CBT</td><td>MRT</td></tr><tr><td>Treatment focus on perpetuating factors</td><td>Treatment focus depending on the relation between the(precipitating, predisposing and perpetuating) factorsand the presented complaints.</td></tr><tr><td>Afterwards feedback at next therapy session</td><td>Immediately feedback during therapy</td></tr><tr><td>Pays no attention to physical sensations</td><td>Stimulating awareness of healthy bodily symptoms</td></tr><tr><td>CBT</td><td>CBT incorporated with principles of mindfulness</td></tr></table> |
c7fd12fba618c62870f009c763f2addac3c1c475f42afbf25a52a3d08ec736c4.png | complex | <table><tr><td></td><td colspan="3">Tender point count (outcome)</td></tr><tr><td></td><td>Model 1β coefficient (95% confidence intervals)</td><td>Model 2β coefficient (95% confidence intervals)</td><td>Model 3β coefficient (95% confidence intervals)</td></tr><tr><td>Psychological distress (HAD) (0–42)</td><td>0.28 (0.20, 0.36)</td><td>0.19 (0.08, 0.30)</td><td>0.19 (0.09, 0.30)</td></tr><tr><td colspan="4">Age</td></tr><tr><td>Youngest (34–57)Middle (58–69)Oldest (70–97)</td><td>(referent)0.50 (−0.9, 1.87)1.30 (−0.09, 2.5)</td><td>(referent)0.45 (−0.88, 1.78)1.46 (0.22, 2.70)</td><td>(referent)0.24 (−1.10, 1.59)0.86 (−0.53, 2.25)</td></tr><tr><td colspan="4">Sex</td></tr><tr><td>MaleFemale</td><td>(referent)1.99 (0.98, 3.35)</td><td>(referent)1.71 (0.61, 2.80)</td><td>(referent)1.86 (0.77, 2.94)</td></tr><tr><td>Catastrophising (PCS) (0–50)</td><td></td><td>−0.03 (−0.13, 0.07)</td><td>−0.03 (−0.13, 0.07)</td></tr><tr><td>Sleep quality (PSQI) (0–21)</td><td></td><td>0.29 (0.07, 0.52)</td><td>0.28 (0.05, 0.50)</td></tr><tr><td colspan="4">Pain beliefs (Brief IPQ)</td></tr><tr><td>Consequences (0–10)Concern (0–10)Coherence (0–10)Timeline (0–10)Treatment control (0–10)Personal control (0–10)Identity (0–10)Emotion (0–10)</td><td></td><td>0.06 (−0.28, 0.39)−0.01 (−0.30, 0.33)0.03 (−0.15, 0.21)0.14 (−0.02, 0.30)0.001 (−0.17, 0.16)0.01 (−0.19, 0.21)0.16 (−0.14, 0.47)−0.09 (−0.43, 0.24)</td><td>−0.001 (−0.32, 0.32)−0.04 (−0.26, 0.34)−0.05 (−0.13, 0.23)0.12 (−0.04, 0.28)0.01 (−0.15, 0.18)0.01 (−0.19, 0.21)0.13 (−0.18, 0.44)−0.12 (−0.45, 0.20)</td></tr><tr><td colspan="4">Smoking</td></tr><tr><td>Never-smokerEx-smokerCurrent smoker</td><td></td><td>(referent)0.25 (−0.80, 1.31)0.69 (−1.37, 2.75)</td><td>(referent)0.19 (−0.86, 1.23)0.40 (−1.80, 2.61)</td></tr><tr><td colspan="4">Alcohol consumption (units)</td></tr><tr><td>(0–60)</td><td></td><td>−0.04 (−0.09, 0.01)</td><td>−0.03 (−0.08, 0.02)</td></tr><tr><td colspan="4">Osteoarthritis count</td></tr><tr><td>0 sites1 site2 sites3 sites</td><td></td><td></td><td>(referent)−0.50 (−1.33, 2.33)0.78 (−1.47, 3.03)5.00 (0.46, 9.54)</td></tr><tr><td>Medication count (0–17)</td><td></td><td></td><td>0.10 (−0.09, 0.28)</td></tr><tr><td>Adjusted <i>R</i> squared</td><td>0.23</td><td>0.29</td><td>0.30</td></tr></table> |
0d9334fdebfa2386967f10ff992a0fc949b9b54b557e8e19ed814c858a9a2f7e.png | complex | <table><tr><td> </td><td> </td><td> </td><td colspan="4"># Significant Loci</td><td> </td><td> </td></tr><tr><td>Species Flock</td><td>GR</td><td>LM PC 1</td><td>LM PC 2</td><td>LM PC 3</td><td>GM PC 2</td><td>Date</td><td>Depth</td><td>Total</td></tr><tr><td>Neuchâtel</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0</td></tr><tr><td>Biel</td><td>0/ 0/ 0</td><td>n/a</td><td>n/a</td><td>n/a</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0</td></tr><tr><td>Thun</td><td>2/ 4/ 4</td><td>3/ 5/ 6</td><td>0/ 0/ 0</td><td>1/ 2/ 2</td><td>0/ 0/ 1</td><td>0/ 0/3</td><td>0/ 0/ 1</td><td>17</td></tr><tr><td>Brienz</td><td>0/ 2/ 4</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 1</td><td>0/ 0/ 0</td><td>5</td></tr><tr><td>Lucerne</td><td>1/ 2/ 5</td><td>0/ 0/ 0</td><td>0/ 0/ 1</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>2/ 3/ 3</td><td>9</td></tr><tr><td>Constance</td><td>0/ 0/ 1</td><td>0/ 0/ 1</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>2</td></tr><tr><td>Walen</td><td>0/ 1/ 1</td><td>0/ 1/ 1</td><td>0/ 0/ 1</td><td>0/ 0/ 0</td><td>0/ 0/ 1</td><td>0/ 0/ 0</td><td>0/ 0/ 2</td><td>6</td></tr><tr><td>Zuerich</td><td>0/ 4/ 4</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>4</td></tr><tr><td>Maggiore</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0/ 0/ 0</td><td>0</td></tr><tr><td>Total</td><td>19</td><td>8</td><td>2</td><td>2</td><td>2</td><td>4</td><td>6</td><td>43</td></tr></table> |
e1d907a13cb07cd4efd26f6e11efc0f972fae7fadf6184f2d7ab41e94897b668.png | simple | <table><tr><td>Variable</td><td>Control group <i>n</i> = 16</td><td>RA nonbiological DMARDs <i>n</i> = 16 </td><td>RA biological DMARDs <i>n</i> = 18</td></tr><tr><td>Age (years)</td><td>51.81 ± 9.75</td><td>51.31 ± 6.70</td><td>52.05 ± 8.26 </td></tr><tr><td>Weight (Kg)</td><td>75.46 ± 22.85</td><td>69.86 ± 14.18</td><td>70.82 ± 19.96</td></tr><tr><td>Height (m)</td><td>1.59 ± 0.05</td><td>1.56 ± 0.07</td><td>1.58 ± 0.05</td></tr><tr><td>BMI (Kg/m<sup>2</sup>)</td><td>29.48 ± 7.35</td><td>28.65 ± 7.09</td><td>28.20 ± 8.19</td></tr><tr><td>WC (cm)</td><td>89.84 ± 17.74</td><td>91.31 ± 15.89</td><td>88.41 ± 27.20</td></tr><tr><td>SBP (mmHg)</td><td>117.50 ± 11.25</td><td>121.00 ± 7.10</td><td>122.11 ± 8.82</td></tr><tr><td>DBP (mmHg)</td><td>75.93 ± 9.86</td><td>79.18 ± 5.23</td><td>78.72 ± 4.72</td></tr></table> |
06cfcba905c461dba48ac38a956ac174f4dda0d339d44e5624d0ef6665f4efc7.png | complex | <table><tr><td rowspan="3">Type of nerves</td><td colspan="4">Outcome variables</td></tr><tr><td colspan="2">Peripheral nerve function (<i>N</i> = 50)</td><td colspan="2"> Number of nerves involved (<i>N</i> = 50)</td></tr><tr><td>Normal, <i>n</i> (%)</td><td>Abnormal, <i>n</i> (%)</td><td><2, <i>n</i> (%)</td><td>≥2, <i>n</i> (%)</td></tr><tr><td>Motor nerve</td><td>23 (46)</td><td>27 (54)</td><td>36 (72)</td><td>14 (28)</td></tr><tr><td>Sensory nerve</td><td>14 (28)</td><td>36 (72)</td><td>23 (46)</td><td>27 (54)</td></tr><tr><td>Mixed nerve</td><td>10 (20)</td><td>40 (80)</td><td>15 (30)</td><td>35 (70)</td></tr></table> |
2bea3dcdc6bd1e1e3b46a4aec51399cae5ea4e9230e57d27665c11ba59301b43.png | simple | <table><tr><td></td><td>1</td><td>2</td><td>3</td><td>4</td><td>5</td><td>6</td><td>7</td><td>8</td><td>9</td><td>10</td><td>11</td><td>12</td><td>13</td><td>14</td><td>15</td><td>16</td><td>17</td><td>18</td><td>19</td><td>20</td><td>21</td></tr><tr><td>1. Communication (FI)</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>2. Demanding (FI)</td><td>0.34</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>3. Colleagues (FI)</td><td>0.21</td><td>0.24</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>4. Supervisor (FI)</td><td>0.35</td><td>0.31</td><td>0.44</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>5. Organization (FI)</td><td>0.49</td><td>0.39</td><td>0.40</td><td>0.70</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>6. Career (FI)</td><td>0.44</td><td>0.44</td><td>0.26</td><td>0.38</td><td>0.51</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>7. Conditions (FI)</td><td>0.32</td><td>0.34</td><td>0.20</td><td>0.20</td><td>0.32</td><td>0.38</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>8. Decision range (FI)</td><td>0.43</td><td>0.47</td><td>0.32</td><td>0.40</td><td>0.53</td><td>0.46</td><td>0.39</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>9. Time aspects (FI)</td><td>0.27</td><td>0.37</td><td>0.25</td><td>0.22</td><td>0.24</td><td>0.34</td><td>0.41</td><td>0.36</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>10. Compensations (FI)</td><td>0.32</td><td>0.33</td><td>0.20</td><td>0.27</td><td>0.37</td><td>0.49</td><td>0.30</td><td>0.38</td><td>0.32</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>11. Framework (FI)</td><td>0.34</td><td>0.36</td><td>0.25</td><td>0.29</td><td>0.37</td><td>0.37</td><td>0.44</td><td>0.45</td><td>0.50</td><td>0.36</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>12. Communication (FS)</td><td>0.73</td><td>0.36</td><td>0.26</td><td>0.39</td><td>0.53</td><td>0.50</td><td>0.37</td><td>0.49</td><td>0.31</td><td>0.41</td><td>0.40</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>13. Demanding (FS)</td><td>0.34</td><td>0.76</td><td>0.28</td><td>0.30</td><td>0.37</td><td>0.47</td><td>0.34</td><td>0.49</td><td>0.39</td><td>0.41</td><td>0.40</td><td>0.40</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>14. Colleagues (FS)</td><td>0.25</td><td>0.25</td><td>0.80</td><td>0.43</td><td>0.43</td><td>0.33</td><td>0.23</td><td>0.35</td><td>0.28</td><td>0.28</td><td>0.27</td><td>0.31</td><td>0.31</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>15. Supervisor (FS)</td><td>0.36</td><td>0.33</td><td>0.36</td><td>0.82</td><td>0.67</td><td>0.39</td><td>0.23</td><td>0.43</td><td>0.26</td><td>0.30</td><td>0.29</td><td>0.43</td><td>0.37</td><td>0.41</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>16. Organization (FS)</td><td>0.52</td><td>0.40</td><td>0.28</td><td>0.37</td><td>0.54</td><td>0.54</td><td>0.39</td><td>0.47</td><td>0.33</td><td>0.55</td><td>0.41</td><td>0.64</td><td>0.47</td><td>0.37</td><td>0.43</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>17. Career (FS)</td><td>0.41</td><td>0.45</td><td>0.28</td><td>0.35</td><td>0.49</td><td>0.76</td><td>0.37</td><td>0.47</td><td>0.33</td><td>0.47</td><td>0.38</td><td>0.52</td><td>0.53</td><td>0.36</td><td>0.41</td><td>0.58</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>18. Conditions (FS)</td><td>0.29</td><td>0.35</td><td>0.27</td><td>0.20</td><td>0.28</td><td>0.35</td><td>0.68</td><td>0.33</td><td>0.35</td><td>0.29</td><td>0.40</td><td>0.36</td><td>0.37</td><td>0.32</td><td>0.24</td><td>0.41</td><td>0.40</td><td></td><td></td><td></td><td></td></tr><tr><td>19. Decision range (FS)</td><td>0.42</td><td>0.56</td><td>0.32</td><td>0.38</td><td>0.48</td><td>0.44</td><td>0.40</td><td>0.64</td><td>0.44</td><td>0.39</td><td>0.48</td><td>0.51</td><td>0.64</td><td>0.38</td><td>0.43</td><td>0.50</td><td>0.48</td><td>0.37</td><td></td><td></td><td></td></tr><tr><td>20. Time aspects (FS)</td><td>0.29</td><td>0.40</td><td>0.31</td><td>0.33</td><td>0.38</td><td>0.38</td><td>0.40</td><td>0.45</td><td>0.66</td><td>0.38</td><td>0.52</td><td>0.36</td><td>0.46</td><td>0.37</td><td>0.38</td><td>0.41</td><td>0.42</td><td>0.40</td><td>0.57</td><td></td><td></td></tr><tr><td>21. Compensations (FS)</td><td>0.31</td><td>0.31</td><td>0.18</td><td>0.23</td><td>0.32</td><td>0.48</td><td>0.25</td><td>0.31</td><td>0.27</td><td>0.74</td><td>0.29</td><td>0.37</td><td>0.37</td><td>0.26</td><td>0.28</td><td>0.48</td><td>0.46</td><td>0.31</td><td>0.31</td><td>0.35</td><td></td></tr><tr><td>22. Framework (FS)</td><td>0.34</td><td>0.38</td><td>0.30</td><td>0.27</td><td>0.40</td><td>0.44</td><td>0.50</td><td>0.43</td><td>0.46</td><td>0.49</td><td>0.50</td><td>0.43</td><td>0.47</td><td>0.38</td><td>0.34</td><td>0.56</td><td>0.51</td><td>0.54</td><td>0.53</td><td>0.57</td><td>0.46</td></tr></table> |
74c589fa92e25c5368ec5a12a8b053cdd37e43a5db7e3f823afc9a7d4f61c532.png | simple | <table><tr><td><i>Standard</i></td><td><i>Mean ± SD of Score</i></td><td><i>Standard Achieved*</i><i>(% of notes)</i></td></tr><tr><td>Contents</td><td>14.4 ± 2.1</td><td>16 (6.8)</td></tr><tr><td>Legibility</td><td>3.9 ± 0.2</td><td>232 (99.1)</td></tr><tr><td>ANKLe</td><td>18.4 ± 2.1</td><td>61 (26.1)</td></tr></table> |
b5079885f6660ddc9db870be679a37a35573216767c72e8b733da664b928645a.png | complex | <table><tr><td rowspan="2">Variables</td><td colspan="3">Group A</td><td colspan="3">Group B</td><td colspan="2">Difference</td><td rowspan="2">**P-value</td></tr><tr><td>Baseline</td><td>3<sup>rd</sup>month</td><td>*P-value</td><td>Baseline</td><td>3<sup>rd</sup>month</td><td>*P-value</td><td>Group A</td><td>Group B</td></tr><tr><td>Pyridinoline</td><td>51.17 ± 87.90</td><td>13.06 ± 5.81</td><td>0.766</td><td>41.01 ± 38.94</td><td>15.67 ± 11.05</td><td>0.268</td><td>−40.8 ± 96.5</td><td>−28.2 ± 42.6</td><td>0.656</td></tr><tr><td>Osteocalcin</td><td>2.20 ± 0.47</td><td>2.5 ± 0.58</td><td>0.564</td><td>2.22 ± 0.60</td><td>2.24 ± 0.82</td><td>0.230</td><td>0.37 ± 0.80</td><td>0.23 ± 0.96</td><td>0.390</td></tr><tr><td>Urine Calcium</td><td>9.09 ± 9.08</td><td>8.10 ± 6.98</td><td>0.045</td><td>6.95 ± 5.03</td><td>5.77 ± 6.31</td><td>0.044</td><td>−1 ± 9.1</td><td>0.21 ± 5.9</td><td>0.683</td></tr><tr><td>Urine Creatinine</td><td>120.55 ± 58.59</td><td>108.23 ± 48.99</td><td>0.273</td><td>111.68 ± 72.39</td><td>130.39 ± 68.47</td><td>0.003</td><td>−11.2 ± 64</td><td>34.6 ± 49.2</td><td>0.029</td></tr><tr><td>Bone Alkaline phosphatase</td><td>24.9 ± 7</td><td>20.8 ± 19.7</td><td>0.014</td><td>23.8 ± 10.4</td><td>20.6 ± 7.5</td><td>0.048</td><td>−4.5 ± 7</td><td>−3 ± 10.8</td><td>0.364</td></tr><tr><td>TNF-α</td><td>91.68 ± 52.92</td><td>88.84 ± 55.75</td><td>0.006</td><td>90.85 ± 27.21</td><td>80.94 ± 28.73</td><td>0.026</td><td>−4.2 ± 26.1</td><td>−12.4 ± 28.2</td><td>0.267</td></tr></table> |
56415768ece4377a204ea273ee5228b50ee79598a50f8a44932e6d5f2caa622f.png | complex | <table><tr><td>Normal alleles</td><td></td><td>Norwegian (present study)</td><td colspan="2">Finnish [43]</td><td>Cuban [65]</td><td>Indian [66]</td><td>Caucasian [67]</td><td>French [26]</td></tr><tr><td></td><td></td><td></td><td>North</td><td>South</td><td></td><td></td><td></td><td></td></tr><tr><td>GAA repeat sizes</td><td>5-12</td><td>83.5 %</td><td>83 %</td><td>79.5 %</td><td>89.1 %</td><td>94.1 %</td><td>80 %</td><td>83 %</td></tr><tr><td></td><td>13-34</td><td>16.5 %</td><td>17 %</td><td>20.5 %</td><td>10.9 %</td><td>5.9 %</td><td>20 %</td><td>17 %</td></tr><tr><td>Alleles range</td><td></td><td>6-34</td><td>6-27</td><td>7-27</td><td>5-31</td><td>7-16</td><td>5-23</td><td>7-34</td></tr></table> |
c2714ccbb2184239ba53c2047d38a06463941d35fb6b1af9d93c830c0e5b3989.png | complex | <table><tr><td colspan="5">Haplotype</td><td colspan="2">Frequency<sup>a</sup></td><td rowspan="2">Chi-square</td><td rowspan="2"><i>P</i><sup>b</sup></td></tr><tr><td>rs929763</td><td>rs732157</td><td>rs2303134</td><td>rs1063310</td><td>rs3805455</td><td>Control</td><td>SLE</td></tr><tr><td>T</td><td>C</td><td>A</td><td>C</td><td>C</td><td>0.406</td><td>0.345</td><td>3.580</td><td>0.03</td></tr><tr><td>A</td><td>C</td><td>A</td><td>C</td><td>C</td><td>0.228</td><td>0.220</td><td>0.091</td><td>0.803</td></tr><tr><td>A</td><td>T</td><td>A</td><td>A</td><td>T</td><td>0.223</td><td>0.185</td><td>1.942</td><td>0.166</td></tr><tr><td>A</td><td>C</td><td>A</td><td>A</td><td>T</td><td>0.037</td><td>0.057</td><td>2.516</td><td>0.334</td></tr><tr><td>T</td><td>C</td><td>A</td><td>A</td><td>T</td><td>0.044</td><td>0.026</td><td>1.893</td><td>0.431</td></tr><tr><td>A</td><td>C</td><td>A</td><td>C</td><td>T</td><td>6.4<i>E</i> − 4</td><td>0.105</td><td>102.6</td><td>4.2E − 24</td></tr><tr><td colspan="5">Other</td><td>0.062</td><td>0.062</td><td>—</td><td>—</td></tr></table> |
1fe9fab8a0ac8e10023f6b669038232b472698c5893442de639433b8adffa319.png | simple | <table><tr><td>Criteria</td><td>Exclusion</td><td>Method</td></tr><tr><td>Significant co-morbid disease that would threaten safety or impair ability to participate in interventions or testing, previous acute knee injury, bilateral severe tibiofemoral OA, severe patellofemoral OA (JSN = 3 using OARSI atlas), no definite medial tibiofemoral OA, severe obesity, low weight.</td><td>Symptomatic or severe coronary artery disease; severe HTN; active cancer other than skin cancer; anemia; dementia; liver disease; COPD; peripheral vascular disease; inability to walk without an assistive device; blindness; type 1 diabetes; type 2 diabetes on thiazolidinedione agents; bilateral severe medial tibiofemoral OA (KL = 4), no definite medial tibiofemoral OA (KL = 0, 1), BMI < 20 or > 45 kg<sup>.</sup>m<sup>-2</sup></td><td>Medical history; physical exam; PA and skyline knee x-ray; height and weight.</td></tr><tr><td>OA disease location and alignment restrictions: predominant knee OA other than medial tibiofemoral OA; valgus, or extreme varus alignment.</td><td>Lateral tibiofemoral OA > medial tibiofemoral OA, severe patellofemoral OA; valgus knee alignment > 2°, or varus alignment > 10°</td><td>Knee PA and skyline view x-rays, lower extremity long x-ray.</td></tr><tr><td>Excess alcohol use</td><td>≥ 21 drinks per week</td><td>Questionnaire</td></tr><tr><td>Inability to finish 18-month study or unlikely to be compliant</td><td>Lives > 50 miles from site or planning to leave area ≥ 3 months during the next 18 months</td><td>Questionnaire, interview</td></tr><tr><td>Conditions that prohibit CT</td><td>BMI > 45 kg<sup>.</sup>m<sup>-2</sup></td><td>height and weight</td></tr><tr><td>Significant cognitive impairment</td><td>diagnosis of dementia or a MoCA score <20</td><td>Medical history, MoCA</td></tr><tr><td>Low Pain</td><td>Pain ≤ 3 on a scale from 0-20</td><td>WOMAC</td></tr></table> |
612f5c3c1ada6c05a58d8c49550fe87c72c022237fd417d62ac1c0efecd173cf.png | complex | <table><tr><td></td><td colspan="3">BASELINE</td><td colspan="3">TIME OF SACRIFICE</td></tr><tr><td></td><td>TC(mM/L)</td><td>HDL-C(mM/L)</td><td>Non HDL-C(mM/L)</td><td>TC(mM/L)</td><td>HDL-C(mM/L)</td><td>Non HDL-C(mM/L)</td></tr><tr><td>SALINE</td><td>0.86 ± 0.07</td><td>0.77 ± 0.09</td><td>0.09 ± 0.07</td><td>2.64 ± 0.29*</td><td>0.65 ± 0.03</td><td>1.99 ± 0.28*</td></tr><tr><td>rHDL</td><td>0.84 ± 0.06</td><td>0.63 ± 0.06</td><td>0.21 ± 0.06</td><td>2.53 ± 0.49*</td><td>0.66 ± 0.06</td><td>1.87 ± 0.46*</td></tr><tr><td>ETC-642</td><td>0.99 ± 0.05</td><td>0.73 ± 0.04</td><td>0.26 ± 0.06</td><td>2.87 ± 0.27*</td><td>0.61 ± 0.05</td><td>2.25 ± 0.26*</td></tr></table> |
d55a7fa557f070f9aa5447852ece08bcd45938d23968f823625b90e8dcbc9e57.png | simple | <table><tr><td>Percentile</td><td>Chlorpyrifos viaIndoor Dust</td><td>Chlorpyrifos viaOutdoor Soils</td><td>Cypermethrin viaIndoor Dust</td><td>Cypermethrin viaOutdoor Soils</td></tr><tr><td>P50</td><td><0.001% (<0.001%, <0.001%)</td><td><0.001% (<0.001%, <0.001%)</td><td><0.001% (<0.001%, <0.001%)</td><td><0.001% (<0.001%, <0.001%)</td></tr><tr><td>P75</td><td>0.002% (0.002%, 0.002%)</td><td>0.001% (0.001%, 0.001%)</td><td>0.004% (0.004%, 0.004%)</td><td><0.001% (<0.001%, <0.001%)</td></tr><tr><td>P90</td><td>0.019% (0.019%, 0.019%)</td><td>0.007% (0.007%, 0.007%)</td><td>0.052% (0.052%, 0.053%)</td><td>0.005% (0.005%, 0.005%)</td></tr><tr><td>P95</td><td>0.079% (0.079%, 0.079%)</td><td>0.029% (0.029%, 0.029%)</td><td>0.208% (0.207%, 0.209%)</td><td>0.023% (0.023%, 0.023%)</td></tr><tr><td>P97.5</td><td>0.254% (0.253%, 0.255%)</td><td>0.102% (0.101%, 0.102%)</td><td>0.629% (0.627%, 0.631%)</td><td>0.080% (0.079%, 0.080%)</td></tr><tr><td>P99</td><td>0.884% (0.880%, 0.887%)</td><td>0.412% (0.410%, 0.414%)</td><td>2.042% (2.035%, 2.049%)</td><td>0.310% (0.308%, 0.311%)</td></tr><tr><td>P99.9</td><td>8.313% (8.234%, 8.392%)</td><td>4.819% (4.782%, 4.856%)</td><td>16.89% (16.75%, 17.04%)</td><td>3.155% (3.124%, 3.186%)</td></tr></table> |
1c702acbb86bbe46e76aad570d1044d91af1d218d49f639dad19239b8554014a.png | simple | <table><tr><td>Cancer</td><td>Mean age ± SD at diagnosis of CD</td></tr><tr><td>Non Hodgkin's lymphoma</td><td>46.1 ± 13.8</td></tr><tr><td>Small bowel</td><td>59 ± 10</td></tr><tr><td>Colon</td><td>51.3 ± 9.4</td></tr><tr><td>Stomach</td><td>53.5 ± 15.4</td></tr><tr><td>Hodgkin's lymphoma</td><td>54.3 ± 6</td></tr><tr><td>Breast</td><td>41.2 ± 12.8</td></tr><tr><td>All neoplasms</td><td>47.6 ± 10.2</td></tr></table> |
d8150a49691065bb344f3e15b3228a6d053607e02944698e1c3faa7b96c06070.png | simple | <table><tr><td>Compound Described</td><td>Mechanism of Action</td><td>Targeting</td><td>References</td></tr><tr><td>PRIMA-1<sup>Met</sup> (APR-246)</td><td>Converted to MQ; MQ binds to thiol groups in the core domain of mutp53 to restore wtp53 function</td><td>Restoration</td><td>Bykov 2002 [66], 2005 [67]Lambert 2009 [68], 2010 [69]</td></tr><tr><td>PhiKan083 or PhiKan7088</td><td>Binding to p53-Y220C specific core cavity and restore wtp53-like folding</td><td>Restoration of p53 Y220C</td><td>Boeckler 2008 [70]Liu 2013 [71]</td></tr><tr><td>PEITC</td><td>Unknown; p53-R172H specific; restores wtp53-like function </td><td>Restoration of p53 R172H</td><td>Aggarwal 2016 [72]</td></tr><tr><td>ReACp53</td><td>Small peptide; blocks amyloid-like aggregation of mutp53 to shift to wtp53-like folding state</td><td>Deaggregation, Restoration</td><td>Soragni 2016 [73]</td></tr><tr><td>pCAP</td><td>Small peptide; binds preferentially to mutp53 when it transiently exhibits wtp53-like conformation to shift the equilibrium towards the wtp53</td><td>Stabilize wtp53 structure</td><td>Tal 2016 [74]</td></tr><tr><td>ZMC-1</td><td>Metallochaperone; increases intracellular zinc level to restore zinc-deficient p53 mutants such as p53-R175H which allows proper wtp53-like folding</td><td>Restoration and activation</td><td>Yu 2012 [75]Blanden 2015 [76]</td></tr><tr><td>RETRA</td><td>Not well known; disrupts mutp53/p73 complexes </td><td>Activation of p73</td><td>Kravchenko 2008 [77]</td></tr><tr><td>Prodigiosin</td><td>Not well known; induces TAp73 expression and disrupts its interaction with mutp53</td><td>Activation of p73</td><td>Hong 2014 [78]</td></tr><tr><td>Chetomin (CTM)</td><td>Binds to Hsp40 and increases the binding of Hsp40 to p53 R175H which leads to restoration of wtp53 conformation</td><td>Restoration of p53 R175H</td><td>Hiraki 2015 [79]</td></tr><tr><td>Hsp90 inhibitors</td><td>e.g., 17AAG and Ganetespib; disrupt chaperone complexes to release and activate MDM2 and/or CHIP which degrade mutp53</td><td>Mutp53 degradation</td><td>Esser 2005 [35]Li 2011 [37]Alexandrova 2015 [15]</td></tr><tr><td>Statin</td><td>e.g., Lovastatin inhibits Hsp40 (by decreasing mevalonate-5-phosphate) or Cerivastatin (more potent) inhibits Hsp90 (by inhibiting HDAC6) to release and reactivate CHIP and MDM2 leading to mutp53 degradation</td><td>Mutp53 degradation</td><td>Parrales 2016 [60]Ingallina 2018 [59]</td></tr></table> |
f61f2c3e18c87648774945d227f45c085022a1256929c8246965cdbf36ea31f2.png | complex | <table><tr><td colspan="4">Attribute and level</td><td rowspan="2">Available colour<sup>a</sup></td></tr><tr><td>Treated (T) or untreated (U)</td><td>Shape</td><td>Size (feet)</td><td>Price (000 TSH)</td></tr><tr><td>T (Olyset brand)</td><td>Rectangular</td><td>4 × 6</td><td>2, 4, 6, 8</td><td>Aqua blue</td></tr><tr><td>T (Olyset brand)</td><td>Rectangular</td><td>6 × 6</td><td>2, 4, 6, 8</td><td>Navy blue and white<sup>b</sup></td></tr><tr><td>U (Safinet brand)</td><td>Rectangular</td><td>4 × 6; 6 × 6</td><td>2, 4, 6, 8</td><td>White</td></tr><tr><td>U (Safinet brand)</td><td>Conical</td><td>3.5 × 6<sup>c;</sup> 6 × 6</td><td>2, 4, 6, 8</td><td>White</td></tr></table> |
931af5005dfede3c204ce43ef8fc4562930b0a77f48bfa1e7145b71c3a9c7acf.png | simple | <table><tr><td></td><td>Mean</td><td>SD</td><td>Range</td><td>n (%) high scores</td><td>n (%) low scores</td></tr><tr><td>PDQ-Carer: Personal and Social Activities</td><td>44.15</td><td>28.82</td><td>0-95.83</td><td>4 (5.5)</td><td>1 (1.4)</td></tr><tr><td>PDQ-Carer: Anxiety and Depression</td><td>46.86</td><td>22.97</td><td>0-100</td><td>2 (2.7)</td><td>1 (1.4)</td></tr><tr><td>PDQ-Carer: Self Care</td><td>32.53</td><td>26.10</td><td>0-90.0</td><td>12 (16.4)</td><td>2 (2.7)</td></tr><tr><td>PDQ-Carer: Strain</td><td>48.17</td><td>22.31</td><td>0-91.67</td><td>3 (4.1)</td><td>1 (1.4)</td></tr><tr><td>SF-36: Physical Functioning</td><td>71.51</td><td>27.81</td><td>5.00-100</td><td>1 (1.4)</td><td>12 (16.4)</td></tr><tr><td>SF-36: Role Physical</td><td>71.92</td><td>39.07</td><td>0-100</td><td>11 (15.1)</td><td>43 (58.9)</td></tr><tr><td>SF-36: Role Emotional</td><td>64.84</td><td>44.41</td><td>0-100</td><td>20 (27.4)</td><td>42 (57.5)</td></tr><tr><td>SF-36: Social Functioning</td><td>67.12</td><td>27.68</td><td>0-100</td><td>1 (1.4)</td><td>18 (24.7)</td></tr><tr><td>SF-36: Mental Health</td><td>62.63</td><td>23.93</td><td>0-100</td><td>1 (1.4)</td><td>3 (4.1)</td></tr><tr><td>SF-36: Energy/Vitality</td><td>54.18</td><td>23.50</td><td>0-100</td><td>1 (1.4)</td><td>2 (2.7)</td></tr><tr><td>SF-36: Pain</td><td>60.22</td><td>28.44</td><td>0-100</td><td>1 (1.4)</td><td>14 (19.2)</td></tr><tr><td>SF-36: General Health Perception</td><td>56.34</td><td>20.84</td><td>5.00-97.00</td><td>1 (1.4)</td><td>1 (1.4)</td></tr></table> |
bf86abb35344ef7fb55e80bff6caaaa9a121736fde90d8a69d166f700abd63a6.png | simple | <table><tr><td></td><td>Diskus</td><td>Turbuhaler</td><td>Difference</td></tr><tr><td>PIFR (L/min)</td><td>77.6, 89.3, 72.2</td><td>55.3, 64.5, 47.8</td><td>significant</td></tr><tr><td>V<sub>I</sub> (L)</td><td>1.63, 2.19, 1.40</td><td>1.11, 1.66, 0.95</td><td>significant</td></tr><tr><td>F<sub>0.3</sub> (L/min)</td><td>64.9, 71.6, 58.3</td><td>47.2, 52.1, 39.1</td><td>significant</td></tr><tr><td>T<sub>PF</sub> (s)</td><td>0.69, 0.89, 0.57</td><td>0.74, 0.93, 0.61</td><td>ns</td></tr></table> |
8da49f83adda1fd515ea085d43bbf0a769340fe6f116c304328238809d66d2a5.png | simple | <table><tr><td>Source of variation</td><td><i>df</i></td><td>SS</td><td>MS</td><td>Est. variance</td><td>Variation (%)</td><td><i>P</i></td></tr><tr><td>Among individuals</td><td>83</td><td>2276.02</td><td>27.42</td><td>8.36</td><td>70.7</td><td>< 0.001</td></tr><tr><td>Within individuals</td><td>157</td><td>543.45</td><td>3.46</td><td>3.46</td><td>29.3</td><td></td></tr><tr><td>Total</td><td>240</td><td>2819.47</td><td></td><td>11.83</td><td>100</td><td></td></tr></table> |
6d0bce26f0966f8db2414d8604b1d36e841298b524761e8cf3dbd54f1466bf61.png | simple | <table><tr><td>Cancer. related Function</td><td>PLS predicted Target genes in the respective functions</td><td>The nos. of cancer related miRNAs associated with the mRNA targets</td></tr><tr><td>Cancer</td><td>ANXA2, BHLHE40, CANX, CAPG, COTL1, CYBA, DDIT4, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1, S100A11, SLC12A8, SLC7A11, SOX4 and UBE2I (20)</td><td>15</td></tr><tr><td>Tumorigenesis</td><td>ANXA2, BHLHE40, CANX, CAPG, COTL1, CYBA, DDIT4, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, NUDT1, OAZ1, ODC1, PRDX2, S100A11, SLC12A8, SLC7A11, SOX4 and UBE2I (22)</td><td>15</td></tr><tr><td>Carcinoma</td><td>ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GSTP1, IFITM1, MMP11, OAZ1, ODC1, S100A11 and SLC7A11 (13)</td><td>12</td></tr><tr><td>Malignant tumor</td><td>ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1, S100A11, SLC7A11 and SOX4 (16)</td><td>12</td></tr><tr><td>Primary tumor</td><td>ANXA2, BHLHE40, CANX, COTL1, CYBA, FTL, GPX1, GSTP1, IFITM1, MIF, MMP11, OAZ1, ODC1, PRDX2, S100A11, SLC7A11 and SOX4 (17)</td><td>12</td></tr><tr><td>Angiogenesis</td><td>ANXA2, CANX and GPX1 (3)</td><td>8</td></tr></table> |
f49c47eb2e4e98287f9a5b739c1b7b4693803384b56e835752079b96d7324b1b.png | simple | <table><tr><td>Severity of inflammatory cell infiltration</td><td>Score 1 (n=7)</td><td>Score 2 (n=10)</td><td>Score 3 (n=17)</td><td>Score 4 (n=12)</td></tr><tr><td>Patients without TBM-IgG3</td><td>4</td><td>3</td><td>2</td><td>6</td></tr><tr><td>Patients with mild deposited TBM-IgG3</td><td>3</td><td>7</td><td>9</td><td>4</td></tr><tr><td>Patients with strong deposited TBM-IgG3</td><td>0</td><td>0</td><td>6</td><td>2</td></tr></table> |
d9b4af31f57edcdb29704050333829dda00c2631129cc036396e2e72581a19e0.png | simple | <table><tr><td></td><td>WC</td><td>WHR</td><td>BMI</td><td>LDL</td><td>Triglycerides</td><td>HDL</td><td>BOP</td><td>IL-1β</td><td>MMP-8</td></tr><tr><td>WHR</td><td>0.640**</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>BMI</td><td>0.664**</td><td>0.924**</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>LDL</td><td>0.217</td><td>0.264*</td><td>0.214</td><td></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>Triglycerides</td><td>0.006</td><td>0.064</td><td>0.059</td><td>−0.147</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td>HDL</td><td>−0.173</td><td>−0.263*</td><td>−0.240*</td><td>0.078</td><td>−0.179</td><td></td><td></td><td></td><td></td></tr><tr><td>BOP</td><td>−0.103</td><td>−0.173</td><td>−0.114</td><td>0.233*</td><td>−0.020</td><td>0.119</td><td></td><td></td><td></td></tr><tr><td>IL-1β</td><td>0.200</td><td>0.270*</td><td>0.340**</td><td>0.342**</td><td>−0.274*</td><td>0.073</td><td>0.220*</td><td></td><td></td></tr><tr><td>MMP-8</td><td>0.254*</td><td>0.242*</td><td>0.234*</td><td>0.332**</td><td>−0.061</td><td>0.114</td><td>0.293**</td><td>0.596**</td><td></td></tr><tr><td>MMP-9</td><td>0.159</td><td>0.144</td><td>0.137</td><td>0.206</td><td>−0.118</td><td>0.013</td><td>0.181</td><td>0.568**</td><td>0.772**</td></tr></table> |
40393ead48ef214a1d44e3bb0c522e8709379d2a028deda9876aa128599bb9a2.png | complex | <table><tr><td>Target</td><td>Primer</td><td>Sequence (5′ → 3′)</td><td>T<sub>a</sub> (°C)</td><td>Reference</td></tr><tr><td rowspan="2">Total bacteria</td><td>UniF</td><td>GTGSTGCAYGGYYGTCGTCA</td><td rowspan="2">60</td><td rowspan="2">[23]</td></tr><tr><td>UniR</td><td>ACGTCRTCCMCNCCTTCCTC</td></tr><tr><td rowspan="2"><i>Bifidobacterium</i></td><td>BIF-F</td><td>TCG CGTC(C/T)GGTGTGAAAG</td><td rowspan="2">58</td><td rowspan="2">[24]</td></tr><tr><td>BIF-R</td><td>CCACATCCAGC(A/G)TCCAC</td></tr><tr><td rowspan="2"><i>Clostridium leptum</i> group</td><td>sg-Clept-F</td><td>GCACAAGCAGTGGAGT</td><td rowspan="2">53</td><td rowspan="2">[25]</td></tr><tr><td>sg-Clept-R3</td><td>CTTCCTCCGTTTTGTCAA</td></tr><tr><td rowspan="2"><i>Bacteroides-Prevotella-Porphyromonas</i></td><td>BPP-F</td><td>GGTGTCGGCTTAAGTGCCAT</td><td rowspan="2">56</td><td rowspan="2">[24]</td></tr><tr><td>BPP-R</td><td>CGGA(C/T)GTAAGGGCCGTGC</td></tr><tr><td rowspan="2"><i>Clostridium coccoides</i> group</td><td>g-ccoc-F</td><td>AAATGACGGTACCTGACTAA</td><td rowspan="2">58</td><td rowspan="2">[26]</td></tr><tr><td>g-ccoc-R</td><td>CTTTGAGTTTCATTCTTGCGAA</td></tr><tr><td rowspan="2"><i>Lactobacillus</i></td><td>Lac1F</td><td>AGCAGTAGGGAATCTTCCA</td><td rowspan="2">58</td><td rowspan="2">[27]</td></tr><tr><td>Lab667</td><td>CACCGCTACACATGGAG</td></tr></table> |
a022c888b30fa816082c1c85cd0cb4cf6572d459de07e7b736280de77c566cdc.png | complex | <table><tr><td>Prognostic factors</td><td>n</td><td>Median survival</td><td>Hazard Ratio</td><td>95% Confidence Interval</td><td><i>P</i></td></tr><tr><td colspan="6">Age, yrs</td></tr><tr><td>< 70</td><td>24</td><td>17.4</td><td></td><td></td><td></td></tr><tr><td>≥ 70</td><td>9</td><td>5.1</td><td>1.81</td><td>1.165–2.813</td><td>0.008</td></tr><tr><td colspan="6">Gender</td></tr><tr><td> Male</td><td>12</td><td>13.0</td><td></td><td></td><td></td></tr><tr><td> Female</td><td>21</td><td>20.0</td><td>0.346</td><td>0.142–0.844</td><td>0.020</td></tr><tr><td colspan="6">Smoking history</td></tr><tr><td> No smoking</td><td>21</td><td>20.0</td><td></td><td></td><td></td></tr><tr><td> Smoking</td><td>12</td><td>5.4</td><td>6.752</td><td>2.418–18.855</td><td><0.001</td></tr><tr><td colspan="6">Thoracoscopic findings</td></tr><tr><td colspan="6"> Pleural nodules</td></tr><tr><td>Yes</td><td>24</td><td>15.6</td><td></td><td></td><td></td></tr><tr><td>No</td><td>6</td><td>17.4</td><td>1.009</td><td>0.399–2.554</td><td>0.985</td></tr><tr><td colspan="6"> Pleural hyperemia</td></tr><tr><td>Yes</td><td>21</td><td>18.9</td><td></td><td></td><td></td></tr><tr><td>No</td><td>9</td><td>15.3</td><td>0.573</td><td>0.223–1.468</td><td>0.246</td></tr><tr><td colspan="6"> Pleural adhesion</td></tr><tr><td>Yes</td><td>6</td><td>5.4</td><td></td><td></td><td></td></tr><tr><td>No</td><td>24</td><td>19.1</td><td>0.277</td><td>0.097–0.788</td><td>0.016</td></tr><tr><td colspan="6"> Pleural edema</td></tr><tr><td>Yes</td><td>9</td><td>18.9</td><td></td><td></td><td></td></tr><tr><td>No</td><td>21</td><td>17.1</td><td>0.908</td><td>0.404–2.038</td><td>0.814</td></tr><tr><td colspan="6"> Pleural plaques</td></tr><tr><td>Yes</td><td>12</td><td>13.0</td><td></td><td></td><td></td></tr><tr><td>No</td><td>18</td><td>19.1</td><td>0.387</td><td>0.170–0.879</td><td>0.023</td></tr><tr><td colspan="6"> Histological type</td></tr><tr><td>Epithelioid</td><td>12</td><td>12.8</td><td></td><td></td><td></td></tr><tr><td>Non-epithelioid</td><td>21</td><td>20.4</td><td>0.095</td><td>0.031–0.293</td><td><0.001</td></tr><tr><td colspan="6"> Staging</td></tr><tr><td>I</td><td>0</td><td></td><td></td><td></td><td></td></tr><tr><td>II</td><td>9</td><td>28.4</td><td></td><td></td><td></td></tr><tr><td>III</td><td>15</td><td>17.1</td><td></td><td></td><td></td></tr><tr><td>IV</td><td>9</td><td>3.0</td><td>21.042</td><td>6.156–71.923</td><td><0.001</td></tr><tr><td colspan="6"> Therapeutic regimen</td></tr><tr><td>Chemotherapy</td><td>21</td><td>20.0</td><td></td><td></td><td></td></tr><tr><td>Chemotherapy and radiotherapy</td><td>3</td><td>15.3</td><td></td><td></td><td></td></tr><tr><td>No therapy</td><td>9</td><td>3.0</td><td>0.087</td><td>0.021–0.359</td><td>0.001</td></tr></table> |
f0f35135854b5c8a9f4ddff602b534d3ac169357af3c84f83b90b080e26723e7.png | complex | <table><tr><td></td><td colspan="3">Mean 24-week change from baseline</td></tr><tr><td></td><td>9.5 mg/24 h patch</td><td>Capsule (3–12 mg/day)</td><td>Placebo</td></tr><tr><td colspan="4">Primary outcomes</td></tr><tr><td>ADAS-cog</td><td>−0.6**</td><td>−0.6**</td><td>1.0</td></tr><tr><td>ADCS-CGIC</td><td>3.9**</td><td>3.9**</td><td>4.2</td></tr><tr><td colspan="4">Secondary outcomes</td></tr><tr><td>MMSE</td><td>1.1**</td><td>0.8**</td><td>0.0</td></tr><tr><td>ADCS-ADL</td><td>−0.1**</td><td>−0.5*</td><td>−2.3</td></tr><tr><td>Trail making test part A</td><td>−12.3***</td><td>−9.8***</td><td>7.7</td></tr><tr><td colspan="4">Adverse events, %</td></tr><tr><td>Nausea</td><td>7.2</td><td>23.1***</td><td>5.0</td></tr><tr><td>Vomiting</td><td>6.2</td><td>17.0***</td><td>3.3</td></tr></table> |
fdc36060b7f2eec55a942c6905ee01a4362cdb2fc7edf21d244aa84d4b51d337.png | complex | <table><tr><td></td><td>n</td><td>%</td><td>Mean</td><td>LCI</td><td>UCI</td></tr><tr><td colspan="6">Maternal outcomes from most recent pregnancy</td></tr><tr><td> Unplanned pregnancy (<i>n</i> = 2039)</td><td>657</td><td>32.2</td><td></td><td></td><td></td></tr><tr><td> Early booking (<i>n</i> = 2038)</td><td>886</td><td>43.5</td><td></td><td></td><td></td></tr><tr><td> Late booking (<i>n</i> = 2038)</td><td>1037</td><td>50.9</td><td></td><td></td><td></td></tr><tr><td> Unbooked (<i>n</i> = 2042)</td><td>114</td><td>5.6</td><td></td><td></td><td></td></tr><tr><td> Low birth weight (<i>n</i> = 2007)</td><td>173</td><td>8.6</td><td></td><td></td><td></td></tr><tr><td> Mean birth weight in grammes (<i>n</i> = 2007)</td><td></td><td></td><td>3036</td><td>3016.66</td><td>3055.85</td></tr><tr><td> Premature (<i>n</i> = 2009)</td><td>31</td><td>1.54</td><td></td><td></td><td></td></tr><tr><td> Caesarian Section (<i>n</i> = 2002)</td><td>65</td><td>3.25</td><td></td><td></td><td></td></tr><tr><td> Extended hospital Stay (4+ days during delivery)</td><td>149</td><td>7.6</td><td></td><td></td><td></td></tr><tr><td colspan="6">Maternal outcomes from previous pregnancies</td></tr><tr><td> Age at first pregnancy (mean) <i>n</i> = 2042</td><td></td><td></td><td>20.22</td><td>20.09</td><td>20.35</td></tr><tr><td> Gravidity (mean no. of lifetime pregnancies) (<i>n</i> = 2042)</td><td></td><td></td><td>2.22</td><td>2.17</td><td>2.27</td></tr><tr><td> History of miscarriage (<i>n</i> = 2039)</td><td>234</td><td>11.5</td><td></td><td></td><td></td></tr><tr><td> History of a stilbirth (<i>n</i> = 2038)</td><td>30</td><td>1.37</td><td></td><td></td><td></td></tr><tr><td> History of a premature baby (<i>n</i> = 2037)</td><td>35</td><td>1.72</td><td></td><td></td><td></td></tr><tr><td> History of a neonatal death (<i>n</i> = 2007)</td><td>188</td><td>9.37</td><td></td><td></td><td></td></tr></table> |
6137c7593f05a18429d0f7690f89d6c6c47dac7c11973b523bedb461edd16ced.png | complex | <table><tr><td>Variable</td><td colspan="2">L<sub>2–4 </sub>BMD</td><td colspan="2">Femoral neck BMD</td></tr><tr><td> </td><td>r</td><td>p</td><td>r</td><td>p</td></tr><tr><td>Trunk rotation ROM</td><td>0.38</td><td>0.02<sup>*</sup></td><td>0.36</td><td>(0.03)<sup>*</sup></td></tr><tr><td>Hip adduction moment (N.m/Kg)</td><td>0.47</td><td>0.005<sup>**</sup></td><td>0.43</td><td>(0.011)<sup>*</sup></td></tr><tr><td>Hip extension moment (N.m/Kg)</td><td>0.44</td><td>0.009 <sup>**</sup></td><td>0.46</td><td>(0.006)<sup>**</sup></td></tr><tr><td>H1S (W/Kg)</td><td>0.55</td><td>0.001<sup>***</sup></td><td>0.64</td><td>(0.0003)<sup>***</sup></td></tr><tr><td>H2S (W/Kg)</td><td>0.41</td><td>0.017 <sup>*</sup></td><td>0.52</td><td>(0.004)<sup>**</sup></td></tr><tr><td>H3S (W/Kg)</td><td>0.50</td><td>0.003 <sup>**</sup></td><td>0.40</td><td>(0.018)<sup>*</sup></td></tr><tr><td>K4S (W/Kg)</td><td>0.51</td><td>0.003 <sup>**</sup></td><td>0.47</td><td>(0.004)<sup>**</sup></td></tr><tr><td>A2S (W/Kg)</td><td>0.66</td><td>0.0001 <sup>***</sup></td><td>0.65</td><td>(0.003)<sup>**</sup></td></tr></table> |
f8d8898f791a588f860c411a789ae59d23f1b8fa61de30e7fe043ee112753b41.png | simple | <table><tr><td>Main effect</td><td>Escape latency</td><td>Path length</td></tr><tr><td>Day 1</td><td><i>F</i> < 1, <i>p</i> = n.s.</td><td><i>F</i> < 1, <i>p</i> = n.s.</td></tr><tr><td>Day 2</td><td><i>F</i><sub>(5, 66)</sub> = 26.29, <i>p</i> < 0.001</td><td><i>F</i><sub>(5, 66)</sub> = 33.94, <i>p</i> < 0.001</td></tr><tr><td>Day 3</td><td><i>F</i><sub>(5, 66)</sub> = 27.73, <i>p</i> < 0.001</td><td><i>F</i><sub>(5, 66)</sub> = 29.83, <i>p</i> < 0.001</td></tr><tr><td>Day 4</td><td><i>F</i><sub>(5, 66)</sub> = 29.86, <i>p</i> < 0.001</td><td><i>F</i><sub>(5, 66)</sub> = 35.68, <i>p</i> < 0.001</td></tr><tr><td>Day 5</td><td><i>F</i><sub>(5, 66)</sub> = 3.78, <i>p</i> = 0.005</td><td><i>F</i><sub>(5, 66)</sub> = 3.73, <i>p</i> = 0.005</td></tr></table> |
9a35272ed055e9b26b768c65e7cecceb07f3000bf3bc51747868c6d7529c21cd.png | complex | <table><tr><td colspan="2">Characteristic</td><td colspan="2">Slept under ITN last night</td><td>Significance (p-value) using chi square test</td></tr><tr><td></td><td></td><td>Yes n(%)</td><td>No n(%)</td><td></td></tr><tr><td>Sex</td><td>Male</td><td>928(39.8)</td><td>1 404(60.2)</td><td>0.001</td></tr><tr><td></td><td>Female</td><td>1 095(44.2)</td><td>1 383(55.8)</td><td></td></tr><tr><td>Residence</td><td>Rural</td><td>552(36.1)</td><td>978(63.9)</td><td>0.005</td></tr><tr><td></td><td>Urban</td><td>1 471(44.8)</td><td>1 809(55.2)</td><td></td></tr><tr><td>Region</td><td>Luapula</td><td>91(28.0)</td><td>234(72.0)</td><td>0.000</td></tr><tr><td></td><td>Central</td><td>236(44.9)</td><td>289(55.1)</td><td></td></tr><tr><td></td><td>Copperbelt</td><td>336(37.1)</td><td>570(62.9)</td><td></td></tr><tr><td></td><td>Eastern</td><td>429(54.1)</td><td>364(45.9)</td><td></td></tr><tr><td></td><td>Lusaka</td><td>151(30.9)</td><td>338(69.1)</td><td></td></tr><tr><td></td><td>North Western</td><td>136(51.7)</td><td>127(48.3)</td><td></td></tr><tr><td></td><td>Northern</td><td>252(48.3)</td><td>270(51.7)</td><td></td></tr><tr><td></td><td>Southern</td><td>207(34.7)</td><td>390(65.3)</td><td></td></tr><tr><td></td><td>Western</td><td>185(47.4)</td><td>205(52.6)</td><td></td></tr><tr><td>Age group (yrs)</td><td>5-9</td><td>932(46.3)</td><td>1 080(53.7)</td><td>0.000</td></tr><tr><td></td><td>10-14</td><td>647(38.8)</td><td>1 022(61.2)</td><td></td></tr><tr><td></td><td>15-19</td><td>444(39.3)</td><td>685(60.7)</td><td></td></tr><tr><td>Number of 5–19 headed by Male or Female</td><td>Male</td><td>1 618(42.2)</td><td>2 213(57.8)</td><td>0.934</td></tr><tr><td></td><td>Female</td><td>405(41.4)</td><td>574(58.6)</td><td></td></tr><tr><td>Wealth quintile</td><td>Lowest</td><td>391(40.4)</td><td>576(59.6)</td><td>0.465</td></tr><tr><td></td><td>Second</td><td>293(48.8)</td><td>307(51.2)</td><td></td></tr><tr><td></td><td>Middle</td><td>407(43.4)</td><td>531(56.6)</td><td></td></tr><tr><td></td><td>Fourth</td><td>450(40.4)</td><td>663(59.6)</td><td></td></tr><tr><td></td><td>Highest</td><td>482(40.4)</td><td>710(59.6)</td><td></td></tr><tr><td>Ratio of nets to sleeping spaces</td><td>Inadequate nets</td><td>653(24.9)</td><td>1 969(75.1)</td><td>0.000</td></tr><tr><td></td><td>Adequate nets</td><td>1 370(62.6)</td><td>818(37.4)</td><td></td></tr><tr><td>Education level of head of household</td><td>Never attended school</td><td>150(41.8)</td><td>209(58.2)</td><td>0.013</td></tr><tr><td></td><td>Primary</td><td>819(41.2)</td><td>1 168(58.8)</td><td></td></tr><tr><td></td><td>Secondary</td><td>764(40.3)</td><td>1 130(59.7)</td><td></td></tr><tr><td></td><td>Tertiary</td><td>290(50.9)</td><td>280(49.1)</td><td></td></tr><tr><td>Age group household head (years)</td><td><25</td><td>95(57.6)</td><td>70(42.4)</td><td>0.001</td></tr><tr><td></td><td>25-34</td><td>508(48.0)</td><td>551(52.0)</td><td></td></tr><tr><td></td><td>35-44</td><td>734(41.8)</td><td>1 020(58.2)</td><td></td></tr><tr><td></td><td>45-59</td><td>514(35.8)</td><td>922(64.2)</td><td></td></tr><tr><td></td><td>60+</td><td>172(43.4)</td><td>224(56.6)</td><td></td></tr><tr><td>Number of ITNs</td><td>1</td><td>268(16.4)</td><td>1 366(83.6)</td><td>0.000</td></tr><tr><td></td><td>2</td><td>773(50.0)</td><td>774(50.0)</td><td></td></tr><tr><td></td><td>3 or more</td><td>982(60.3)</td><td>647(39.7)</td><td></td></tr></table> |
79249e803ceb5ec4718dfa83393d36dbe7062a3c44658644880d8cbcc60c2998.png | simple | <table><tr><td>Item</td><td>Wanted to know the sex of the baby</td><td>Did not want to know the sex of the baby</td><td><i>p</i> value</td></tr><tr><td>Mean age, years</td><td>29.4</td><td>29.4</td><td>0.80</td></tr><tr><td></td><td><i>n</i> (%)</td><td><i>n</i> (%)</td><td></td></tr><tr><td>Age groups</td><td></td><td></td><td>0.99</td></tr><tr><td> 17–24 years</td><td>214 (16.1)</td><td>160 (15.9)</td><td></td></tr><tr><td> 25–34 years</td><td>923 (69.4)</td><td>697 (69.4)</td><td></td></tr><tr><td> 35–47 years</td><td>193 (14.5)</td><td>148 (14.6)</td><td></td></tr><tr><td>Origin</td><td></td><td></td><td>0.45</td></tr><tr><td> Nordic</td><td>1245 (92.1)</td><td>950 (92.3)</td><td></td></tr><tr><td> Non-Nordic</td><td>107 (7.9)</td><td>79 (7.7)</td><td></td></tr><tr><td>Education</td><td></td><td></td><td>0.32</td></tr><tr><td> Low</td><td>584 (43.3)</td><td>465 (45.5)</td><td></td></tr><tr><td> High</td><td>764 (56.7)</td><td>558 (54.5)</td><td></td></tr><tr><td>Previous children</td><td></td><td></td><td>0.43</td></tr><tr><td> No previous childen</td><td>624 (46.0)</td><td>456 (44.3)</td><td></td></tr><tr><td> Has previous children</td><td>732 (54.0)</td><td>573 (55.7)</td><td></td></tr><tr><td>Income</td><td></td><td></td><td>0.53</td></tr><tr><td> Low</td><td>620 (46.9)</td><td>485 (48.2)</td><td></td></tr><tr><td> High</td><td>703 (53.1)</td><td>521 (51.8)</td><td></td></tr><tr><td>Pregnancy planning</td><td></td><td></td><td>0.34</td></tr><tr><td> Very/fairly planned</td><td>1004 (74.7)</td><td>781 (76.4)</td><td></td></tr><tr><td> Neither planned nor unplanned</td><td>180 (13.4)</td><td>139 (13.6)</td><td></td></tr><tr><td> Very/fairly unplanned</td><td>160 (11.9)</td><td>102 (10.0)</td><td></td></tr><tr><td>Gone through another method of fetal diagnostics</td><td>594 (43.8)</td><td>388 (37.7)</td><td><0.001</td></tr><tr><td>Importance of religion</td><td></td><td></td><td>0.44</td></tr><tr><td> Great importance</td><td>146 (10.9)</td><td>127 (12.4)</td><td></td></tr><tr><td> Neither important nor unimportant</td><td>296 (22.0)</td><td>231 (22.5)</td><td></td></tr><tr><td> Little importance</td><td>903 (67.1)</td><td>667 (65.1)</td><td></td></tr></table> |
6bf7a7dd13bfaea5f382cbcbc205b9cebbdb6d356c53c74ad50fa084ed34bdfe.png | simple | <table><tr><td>Cluster</td><td>Cluster</td><td>Voxel</td><td>Voxel</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td><i>P</i></td><td>Size</td><td><i>P</i></td><td><i>T</i></td><td><i>x</i></td><td><i>y</i></td><td><i>z</i></td><td>Side</td><td>Location</td></tr><tr><td>0.008</td><td>22</td><td>0.004</td><td>5.15</td><td>−56</td><td>−18</td><td>40</td><td>L</td><td>IPL</td></tr><tr><td>0.011</td><td>16</td><td>0.008</td><td>5.16</td><td>−38</td><td>−42</td><td>60</td><td>L</td><td>aIPS</td></tr></table> |
87f93bf7920fb17c67231d6cfcbd47ebfc46b34ce11d3cfda900f6d4788afee5.png | simple | <table><tr><td>Demographic group</td><td>% of survey respondents who travelled to the mainland in previous 8 weeks in 2013 (N)</td><td>% of survey respondents who travelled to the mainland in previous 8 weeks in 2014 (N)</td></tr><tr><td>Overall</td><td>8.1% (20,536)</td><td>8.7% (20,880)</td></tr><tr><td>Children aged 2-14</td><td>6.2% (7,555)</td><td>6.1% (8,039)</td></tr><tr><td>Aged 15 or over</td><td>9.6% (11,498)</td><td>10.9% (11,436)</td></tr><tr><td>Living in urban sites</td><td>10.9% (12,080)</td><td>11.9% (12,309)</td></tr><tr><td>Living in rural sites</td><td>4.0% (8,456)</td><td>4.1% (8,571)</td></tr><tr><td>Highest SES quintile</td><td>9.8% (4,686)</td><td>14.3% (5,496)</td></tr><tr><td>Lowest SES quintile</td><td>3.9% (2,499)</td><td>4.6% (2,974)</td></tr></table> |
bdc56d5cf410678c46f86bcabe95af8522d938111857adb98da418d2a98fe7e9.png | complex | <table><tr><td>S.N.</td><td>Name of genotype</td><td>Pedigree/source</td></tr><tr><td colspan="3"> <i>I. Elite coffee genotypes used for genetic diversity in the cultivated genepool</i></td></tr><tr><td>1</td><td>Taferikela</td><td><i>C. arabica</i>; Pureline from Ethiopian collections</td></tr><tr><td>2</td><td>HdeT</td><td><i>C. arabica</i>; Amphidiploid coffee, a natural hybrid from <i>C. arabica </i>and <i>C. canephora</i></td></tr><tr><td>3</td><td>S2790</td><td><i>C. arabica</i>; HdeT × Tafarikela, selection</td></tr><tr><td>4</td><td>S2792</td><td><i>C. arabica</i>; Tafarikela × HdeT, selection</td></tr><tr><td>5</td><td>S10</td><td><i>C. arabica</i>; Double Cross Hybrid; Caturra with Cioccie and S.795 (both arabica)</td></tr><tr><td>6</td><td>S11</td><td><i>C. arabica</i>; Amphidiploid, <i>C. liberica </i>× <i>C. eugenioides</i></td></tr><tr><td>7</td><td>BM</td><td><i>C. arabica</i>; Blue Mountain Pure line</td></tr><tr><td>8</td><td>Agaro-Sln4</td><td><i>C. arabica</i>; Pureline from Ethiopian collections</td></tr><tr><td>9</td><td>Kagganahalla</td><td><i>C. canephora</i>; Selection</td></tr><tr><td>10</td><td>BR9</td><td><i>C. canephora</i>; Selection</td></tr><tr><td>11</td><td>BR11</td><td><i>C. canephora</i>; Selection</td></tr><tr><td>12</td><td>CXR</td><td><i>C. canephora</i>; Hybrid of <i>C. congenis </i>× <i>C. canephora</i></td></tr><tr><td>13</td><td>L1Valley</td><td><i>C. canephora</i>; Selection</td></tr><tr><td>14</td><td>S3329</td><td><i>C. canephora</i>; Selection</td></tr><tr><td>15</td><td>S3334</td><td><i>C. canephora</i>; Selection</td></tr><tr><td>16</td><td>Sln27</td><td><i>C. canephora</i>; Pure line</td></tr><tr><td colspan="3"> <i>II. Parents and mapping population used for testing utility in mapping analysis</i></td></tr><tr><td colspan="3"> Parents: CXR (12) and Kagganahalla (9); Mapping population: 175 segregating progenies</td></tr><tr><td colspan="3"> <i>III. Species of Coffea and Psilanthus (related taxa of cultivated coffee) used for transferability studies</i></td></tr><tr><td>a</td><td><i>C. congensis</i></td><td>Erythrocoffea (W. & C. Africa)</td></tr><tr><td>b</td><td><i>C. excelsa</i></td><td>Pachycoffea (Srilanka)</td></tr><tr><td>c</td><td><i>C. liberica</i></td><td>Pachycoffea (W. & C. Africa)</td></tr><tr><td>d</td><td><i>C. abeokuteae</i></td><td>Pachycoffea (Srilanka)</td></tr><tr><td>e</td><td><i>C. dewevrei</i></td><td>Pachycoffea (USDA)</td></tr><tr><td>f</td><td><i>C. arnoldiana</i></td><td>Pachycoffea (SanMarino)</td></tr><tr><td>g</td><td><i>C. aruwemiensis</i></td><td>Pachycoffea (SanMarino)</td></tr><tr><td>h</td><td><i>C. eugenioides</i></td><td>Mozambicoffea (C. Africa)</td></tr><tr><td>i</td><td><i>C. racemosa</i></td><td>Mozambicoffea (E. Africa)</td></tr><tr><td>j</td><td><i>C. salvatrix</i></td><td>Mozambicoffea (E. Africa)</td></tr><tr><td>k</td><td><i>C. kapakata</i></td><td>Mozambicoffea (C. Africa)</td></tr><tr><td>l</td><td><i>C. stenophylla</i></td><td>Melanocoffea (W. Africa)</td></tr><tr><td>m</td><td><i>P. wightiana</i></td><td>Paracoffea (India)</td></tr><tr><td>n</td><td><i>P. bengalenis</i></td><td>Paracoffea (India)</td></tr></table> |
3de2aac5a66bd1deed6ea4e71e018a3588b1c84ec871dce66841f51c37dceb0c.png | simple | <table><tr><td>Description</td><td>Answers</td><td><i>p</i>-value model</td><td>OR<sup>b</sup></td><td>95 % CI<sup>c</sup></td></tr><tr><td>Work sequence depending on healthy before sick pigs (Ref.<sup>a</sup> Yes)</td><td>No</td><td><0.01</td><td>16.68</td><td>3.4-81.8</td></tr><tr><td>Working on other farms (Ref. No)</td><td>Yes</td><td><0.01</td><td>0.05</td><td>0.006-0.4</td></tr><tr><td>Distance to the next pig farm (Ref. ≥ 500 metres)</td><td><500 metres</td><td>0.01</td><td>9.88</td><td>1.7-57.1</td></tr><tr><td>Visitor boots available (Ref. No boots available)</td><td>Yes, clean</td><td>0.97</td><td>1.03</td><td>0.2-4.7</td></tr><tr><td></td><td>Yes, dirty</td><td>0.01</td><td>0.06</td><td>0.006-0.5</td></tr><tr><td>Analysis of production parameters (Ref. by others (external))</td><td>By farmer (program, computer, written, none)</td><td>0.01</td><td>0.12</td><td>0.02-0.6</td></tr><tr><td>Application of homoeopathic agents (Ref. Yes)</td><td>No</td><td>0.02</td><td>10.49</td><td>1.4-78.8</td></tr><tr><td>Mixing pigs of different suppliers within the same pen (Ref. No mixing)</td><td>Yes</td><td>0.05</td><td>4.16</td><td>1.0-17.4</td></tr></table> |
c58a1ca68bd6daab0a3f14cd3aae869f0eb709aa709c873f3f9b47b917767692.png | simple | <table><tr><td>Categories</td><td>Sepsis/SS group(<i>n</i> = 50)</td><td>Non-sepsis group(<i>n</i> = 20)</td><td><i>p</i> value</td></tr><tr><td>WBC (×10<sup>9</sup>/L)</td><td>11.9 (7.9-15.3)</td><td>9.7 (7.3-13.4)</td><td>0.170</td></tr><tr><td>hs-CRP (mg/L)</td><td>143.4 (82.6-212.4)</td><td>50.9 (32.3-74.1)</td><td>0.000</td></tr><tr><td>PCT (ng/ml)</td><td>0.84 (0.36-5.8)</td><td>0.08 (0.05-0.54)</td><td>0.000</td></tr></table> |
04534cb25f2fdeab83d22feb98f7e26f3a629a81242269fa625967c8eb603c2c.png | complex | <table><tr><td rowspan="2" colspan="2"></td><td>Alive</td><td>Dead</td><td rowspan="2"><i>p</i>-Value</td></tr><tr><td><i>n</i> = 41,516</td><td><i>n</i> = 1346</td></tr><tr><td rowspan="3">Mobility (%)</td><td>No problems</td><td>3210 (7.7)</td><td>52 (3.9)</td><td rowspan="3"><0.001</td></tr><tr><td>Moderate problems</td><td>38,190 (92.0)</td><td>1279 (95.0)</td></tr><tr><td>Severe problems</td><td>116 (0.3)</td><td>15 (1.1)</td></tr><tr><td rowspan="3">Self-care (%)</td><td>No problems</td><td>32,066 (77.2)</td><td>910 (67.6)</td><td rowspan="3"><0.001</td></tr><tr><td>Moderate problems</td><td>9102 (21.9)</td><td>403 (29.9)</td></tr><tr><td>Severe problems</td><td>348 (0.8)</td><td>33 (2.5)</td></tr><tr><td rowspan="3">Usual activities (%)</td><td>No problems</td><td>16,086 (38.7)</td><td>460 (34.2)</td><td rowspan="3"><0.001</td></tr><tr><td>Moderate problems</td><td>21,125 (50.9)</td><td>684 (50.8)</td></tr><tr><td>Severe problems</td><td>4305 (10.4)</td><td>202 (15.0)</td></tr><tr><td rowspan="3">Pain/discomfort (%)</td><td>No problems</td><td>631 (1.5)</td><td>16 (1.2)</td><td rowspan="3"><0.001</td></tr><tr><td>Moderate problems</td><td>23,822 (57.4)</td><td>706 (52.5)</td></tr><tr><td>Severe problems</td><td>17,063 (41.1)</td><td>624 (46.4)</td></tr><tr><td rowspan="3">Anxiety/depression (%)</td><td>No problems</td><td>23,963 (57.7)</td><td>711 (52.8)</td><td rowspan="3"><0.001</td></tr><tr><td>Moderate problems</td><td>16,079 (38.7)</td><td>568 (42.2)</td></tr><tr><td>Severe problems</td><td>1474 (3.6)</td><td>67 (5.0)</td></tr><tr><td>EQ VAS score (SD)</td><td></td><td>54.77 (22.17)</td><td>50.61 (21.76)</td><td><0.001</td></tr><tr><td>Pain VAS score (SD)</td><td></td><td>62.39 (15.91)</td><td>62.67 (17.34)</td><td>0.53</td></tr><tr><td>Females (%)</td><td></td><td>23,358 (56.3)</td><td>633 (47.0)</td><td><0.001</td></tr><tr><td>Age (SD)</td><td></td><td>67.70 (10.09)</td><td>75.76 (8.83)</td><td><0.001</td></tr><tr><td rowspan="3">Educational level (%)</td><td>low</td><td>14,018 (33.8)</td><td>658 (48.9)</td><td rowspan="3"><0.001</td></tr><tr><td>middle</td><td>17,038 (41.0)</td><td>466 (34.6)</td></tr><tr><td>high</td><td>10,460 (25.2)</td><td>222 (16.5)</td></tr><tr><td rowspan="4">Hospital (%)</td><td>University</td><td>3018 (7.3)</td><td>117 (8.7)</td><td rowspan="4"><0.001</td></tr><tr><td>County</td><td>13,026 (31.4)</td><td>464 (34.5)</td></tr><tr><td>Rural</td><td>17,490 (42.1)</td><td>603 (44.8)</td></tr><tr><td>Private</td><td>7982 (19.2)</td><td>162 (12.0)</td></tr><tr><td rowspan="5">Fixation (%)</td><td>Cemented</td><td>28,237 (68.4)</td><td>1168 (87.0)</td><td rowspan="5"><0.001</td></tr><tr><td>Uncemented</td><td>6363 (15.4)</td><td>58 (4.3)</td></tr><tr><td>Hybrid</td><td>536 (1.3)</td><td>12 (0.9)</td></tr><tr><td>Reverse hybrid</td><td>5503 (13.3)</td><td>102 (7.6)</td></tr><tr><td>Resurfacing</td><td>639 (1.5)</td><td>2 (0.1)</td></tr></table> |
e705f491c9cfbfa0961208eb814b12471168fa69b8bb290044c821d18d906850.png | complex | <table><tr><td rowspan="2">Age group (years)</td><td colspan="2">Sex </td><td rowspan="2">Number of AWE (%)</td></tr><tr><td>M (%)</td><td>F (%)</td></tr><tr><td>11–13</td><td>4 (26.7)</td><td>0</td><td>4 (22.2)</td></tr><tr><td>14–16</td><td>2 (13.3)</td><td>0</td><td>2 (11.1)</td></tr><tr><td>17–19</td><td>9 (60)</td><td>3 (100)</td><td>12 (66.7)</td></tr><tr><td>Total</td><td>15 (100)</td><td>3 (100)</td><td>18 (100)</td></tr></table> |
e15eb1f0175deb8ec697843593ad5be253e07d44bdffb4172873c5accb2a1d25.png | simple | <table><tr><td>Zebrafishglucose-related immune protein</td><td>p-value</td><td>GO annotation</td></tr><tr><td><i>gpia</i></td><td>0.004833</td><td>humoral immune response</td></tr><tr><td><i>hif1ab</i></td><td>0.0065</td><td>inflammatory response</td></tr><tr><td><i>ins</i></td><td>0.006833</td><td>glucose transport/T cell activation</td></tr></table> |
2630e749c0b1fef1dab1b754c1eb4e88886d6f4f02c753114b3e7dccef50eb53.png | complex | <table><tr><td>Genus</td><td>Species</td><td>Name</td><td>Feeding Strategy</td><td>Genome Size (Mb)</td><td>Proteome size</td><td>CWDE’s Identified</td></tr><tr><td><i>Bursaphelenchus</i></td><td><i>B. xylophilus</i></td><td>Pine wood nematode</td><td>Stem/Bulb Nematodes</td><td>73.09</td><td>18,074</td><td>119</td></tr><tr><td><i>Globodera</i></td><td><i>G. pallida</i></td><td>Potato cyst nematode</td><td>Sedentary Endo-parasites</td><td>123.63</td><td>16,417</td><td>100</td></tr><tr><td rowspan="3"><i>Meloidogyne</i></td><td><i>M. floridensis</i></td><td>Peach root-knot nematode</td><td>Sedentary Endo-parasites</td><td>96.67</td><td>21,038</td><td>102</td></tr><tr><td><i>M. hapla</i></td><td>Northern root-knot nematode</td><td>Sedentary Endo-parasites</td><td>53.01</td><td>14,420</td><td>78</td></tr><tr><td><i>M. incognita</i></td><td>Southern root-knot nematode</td><td>Sedentary Endo-parasites</td><td>82.1</td><td>20,365</td><td>131</td></tr></table> |
af728da180c10ceae6cd8caba2290e3ab9115f2779ade3c859aa23bedfcd3310.png | simple | <table><tr><td></td><td>Overall (%)</td></tr><tr><td>Returned home with the presence of adults</td><td>42.3</td></tr><tr><td>Returned home without the presence of adults</td><td>12.5</td></tr><tr><td>Returned home with the presence of siblings</td><td>10.9</td></tr><tr><td>Participated in extracurricular activity</td><td>23.5</td></tr><tr><td>Socializing with friends without the presence of adults</td><td>9.9</td></tr><tr><td>Wandering the streets alone</td><td>0.9</td></tr></table> |
edb2ceb9518132053d0911882a9a269762a1ad2f9cb90398a7bf8c07cb43eae7.png | complex | <table><tr><td>Type of Tool</td><td>Respondents</td><td>Number of Interviews (Key Informat Interviews)</td><td>Number of participants per interview</td><td>Total number of participants</td></tr><tr><td rowspan="2">Key Informat Interviews</td><td>Medical Officers, Clinical Care Experts and Maternal and Child Health Cordinator</td><td>12 (3 in each of the 4 districts)</td><td>1</td><td>12</td></tr><tr><td>Health Facility in-charge</td><td>4 (1 in each of the 4 districts)</td><td>1</td><td>4</td></tr><tr><td rowspan="2">Focus Group Discussions</td><td>Mothers of children below one year</td><td>4 (1 in each of the health facilities from each district)</td><td>8–10</td><td>38</td></tr><tr><td>Community Health Volunteers (CHWs, NHC, TBAs)<sup>a</sup></td><td>4 (1 in each of the health facilities from each district)</td><td>6–8</td><td>30</td></tr><tr><td colspan="3">Total</td><td>24</td><td>84</td></tr></table> |
1c8d7fa6f1e33bfac80b49bc063e13a7730e04e503fdd33d15e432786aba83fd.png | simple | <table><tr><td>Type of organization</td><td>Organization/department</td><td>Position</td><td>No. of interviewees</td></tr><tr><td>National Ministry of Health</td><td>Monitoring and Evaluation</td><td>Head, M&E</td><td>1</td></tr><tr><td></td><td>Health information system</td><td>Head, HIS</td><td>1</td></tr><tr><td></td><td>Health Financing</td><td>Head, Health financing division</td><td>2</td></tr><tr><td>National Treasury</td><td>IFMIS</td><td></td><td>2</td></tr><tr><td></td><td>e-PROMIS</td><td>Director</td><td>1</td></tr><tr><td>Social Insurance Agency</td><td>National Hospital Insurance Fund</td><td></td><td>1</td></tr><tr><td>University of Nairobi</td><td>School of Economics</td><td>Senior Lecturer</td><td>1</td></tr><tr><td></td><td>School of Public Health</td><td>Head, Health system and policy department</td><td>1</td></tr><tr><td>Tertiary Hospital</td><td>Kenyatta hospital</td><td></td><td>1</td></tr><tr><td>Multilateral organizations</td><td>WHO</td><td>Health System Advisor</td><td>1</td></tr><tr><td></td><td>World Bank</td><td>Regional Health Specialist</td><td>1</td></tr><tr><td></td><td>DFID</td><td>Secretary, Health & Education departments</td><td>1</td></tr><tr><td>USAID or PEPFAR funded</td><td>Abt Associates</td><td></td><td>1</td></tr><tr><td> implementers</td><td>i-TECH</td><td></td><td>1</td></tr><tr><td></td><td>Futures group</td><td></td><td>3</td></tr><tr><td>Nairobi County</td><td>Mbagathi District Hospital</td><td></td><td>4</td></tr><tr><td>Kajiado County</td><td>County administration</td><td></td><td>2</td></tr><tr><td></td><td>Hospital</td><td>Health administration officer</td><td>1</td></tr><tr><td>Muranga County</td><td>County administration</td><td></td><td>2</td></tr><tr><td></td><td>Muranga County Hospital</td><td>Medical Superintendent</td><td>1</td></tr><tr><td>Nakuru County</td><td>County administration</td><td></td><td>1</td></tr><tr><td></td><td>Nakuru Regional Hospital</td><td></td><td>2</td></tr><tr><td>TOTAL</td><td></td><td></td><td>32</td></tr></table> |
bab6a7aeb3c3acb1ddc60ee7610bd08bad338e2f880b1af333c89bc7022c42b5.png | complex | <table><tr><td>Coverage</td><td></td><td colspan="2">35×</td><td colspan="2">70×</td><td colspan="2">140×</td></tr><tr><td>Error rate</td><td></td><td>1<i>%</i></td><td>3<i>%</i></td><td>1<i>%</i></td><td>3<i>%</i></td><td>1<i>%</i></td><td>3<i>%</i></td></tr><tr><td><i>α</i> for Lighter</td><td></td><td>0.2</td><td>0.2</td><td>0.1</td><td>0.1</td><td>0.05</td><td>0.05</td></tr><tr><td></td><td>Quake</td><td>89.68</td><td>48.77</td><td>89.64</td><td>48.82</td><td>89.59</td><td>48.78</td></tr><tr><td></td><td>SOAPec</td><td>57.71</td><td>38.00</td><td>57.57</td><td>37.71</td><td>57.09</td><td>36.76</td></tr><tr><td>Recall</td><td>Musket</td><td>93.75</td><td>92.62</td><td>93.73</td><td>92.64</td><td>93.73</td><td>92.63</td></tr><tr><td></td><td>Bless</td><td>99.81</td><td>99.33</td><td>99.82</td><td>99.58</td><td>99.82</td><td>99.58</td></tr><tr><td></td><td>Lighter</td><td>99.87</td><td>98.53</td><td>99.84</td><td>98.72</td><td>99.86</td><td>98.78</td></tr><tr><td></td><td>Quake</td><td>99.99</td><td>99.99</td><td>99.99</td><td>99.99</td><td>99.99</td><td>99.99</td></tr><tr><td></td><td>SOAPec</td><td>99.99</td><td>100.00</td><td>99.99</td><td>99.99</td><td>99.99</td><td>99.99</td></tr><tr><td>Precision</td><td>Musket</td><td>99.99</td><td>99.93</td><td>99.99</td><td>99.93</td><td>99.99</td><td>99.93</td></tr><tr><td></td><td>Bless</td><td>99.73</td><td>98.86</td><td>99.73</td><td>99.35</td><td>99.72</td><td>99.36</td></tr><tr><td></td><td>Lighter</td><td>99.98</td><td>99.96</td><td>99.98</td><td>99.96</td><td>99.98</td><td>99.96</td></tr><tr><td></td><td>Quake</td><td>94.55</td><td>65.56</td><td>94.54</td><td>65.61</td><td>94.51</td><td>65.57</td></tr><tr><td></td><td>SOAPec</td><td>73.18</td><td>55.07</td><td>73.07</td><td>54.77</td><td>72.68</td><td>53.75</td></tr><tr><td><i>F</i> score</td><td>Musket</td><td>96.77</td><td>96.14</td><td>96.76</td><td>96.15</td><td>96.76</td><td>96.15</td></tr><tr><td></td><td>Bless</td><td>99.77</td><td>99.09</td><td>99.77</td><td>99.47</td><td>99.77</td><td>99.47</td></tr><tr><td></td><td>Lighter</td><td>99.93</td><td>99.24</td><td>99.91</td><td>99.33</td><td>99.92</td><td>99.36</td></tr><tr><td></td><td>Quake</td><td>89.67</td><td>48.76</td><td>89.64</td><td>48.82</td><td>89.59</td><td>48.78</td></tr><tr><td></td><td>SOAPec</td><td>57.70</td><td>38.00</td><td>57.57</td><td>37.71</td><td>57.09</td><td>36.75</td></tr><tr><td>Gain</td><td>Musket</td><td>93.74</td><td>92.56</td><td>93.72</td><td>92.58</td><td>93.72</td><td>92.57</td></tr><tr><td></td><td>Bless</td><td>99.54</td><td>98.19</td><td>99.54</td><td>98.93</td><td>99.54</td><td>98.94</td></tr><tr><td></td><td>Lighter</td><td>99.85</td><td>98.49</td><td>99.81</td><td>98.68</td><td>99.84</td><td>98.73</td></tr><tr><td></td><td>Quake</td><td>17</td><td>17</td><td>17</td><td>17</td><td>17</td><td>17</td></tr><tr><td></td><td>SOAPec</td><td>17</td><td>17</td><td>17</td><td>17</td><td>17</td><td>17</td></tr><tr><td><i>k</i></td><td>Musket</td><td>23</td><td>19</td><td>23</td><td>19</td><td>23</td><td>19</td></tr><tr><td></td><td>Bless</td><td>31</td><td>23</td><td>31</td><td>23</td><td>31</td><td>23</td></tr><tr><td></td><td>Lighter</td><td>23</td><td>19</td><td>23</td><td>19</td><td>23</td><td>19</td></tr></table> |
d0f07853e9e5755a77b96f323bc26147dff45eb4784deded02745d2c22d646bd.png | simple | <table><tr><td>CT score</td><td>CT status</td><td>Morphology features on CT</td><td>EMVI status</td></tr><tr><td>0</td><td>Definite No</td><td>Absence of tumor extension beyond the colon wall/ Tumor extension through the colon wall but no adjacent vessels (Mesenteric contralateral side)</td><td>Negative</td></tr><tr><td>1</td><td>Suspicious No</td><td>Stranding in proximity of vessels but no tumor density in vessels (Mesenteric side)</td><td>Negative</td></tr><tr><td>2</td><td>Suspicious Yes</td><td>Similar tumor density in adjacent vessels; vessel expansion by tumor (Mesenteric side)</td><td>Positive</td></tr><tr><td>3</td><td>Definite Yes</td><td>Similar tumor density in adjacent vessels; Irregular vessel contour by tumor (Mesenteric side)</td><td>Positive</td></tr></table> |
7b1bf8aa2dcbf849a5374d09a9acbf6f07c88e2dcf8f2ff8c18f63de863cfddf.png | complex | <table><tr><td rowspan="2">Characteristics</td><td rowspan="2">Total</td><td colspan="2">HOXA1 expression</td><td rowspan="2"><i>P</i> value</td><td colspan="2">Cyclin D1 expression</td><td rowspan="2"><i>P</i> value</td></tr><tr><td>Negative (120)</td><td>Positive (144)</td><td>Negative (127)</td><td>Positive (137)</td></tr><tr><td>Age(years)</td><td></td><td></td><td></td><td>0.457</td><td></td><td></td><td>0.845</td></tr><tr><td> <65</td><td>121</td><td>58</td><td>63</td><td></td><td>59</td><td>62</td><td></td></tr><tr><td> ≥65</td><td>143</td><td>62</td><td>81</td><td></td><td>68</td><td>75</td><td></td></tr><tr><td>Gender</td><td></td><td></td><td></td><td>0.095</td><td></td><td></td><td>0.712</td></tr><tr><td> Male</td><td>157</td><td>78</td><td>79</td><td></td><td>77</td><td>80</td><td></td></tr><tr><td> Female</td><td>107</td><td>42</td><td>65</td><td></td><td>50</td><td>57</td><td></td></tr><tr><td>T stage</td><td></td><td></td><td></td><td>0.040*</td><td></td><td></td><td>0.816</td></tr><tr><td> T1</td><td>76</td><td>44</td><td>32</td><td></td><td>38</td><td>38</td><td></td></tr><tr><td> T2</td><td>42</td><td>20</td><td>22</td><td></td><td>22</td><td>20</td><td></td></tr><tr><td> T3</td><td>118</td><td>47</td><td>71</td><td></td><td>53</td><td>65</td><td></td></tr><tr><td> T4</td><td>28</td><td>9</td><td>19</td><td></td><td>14</td><td>14</td><td></td></tr><tr><td>N stage</td><td></td><td></td><td></td><td>0.004*</td><td></td><td></td><td>0.179</td></tr><tr><td> N0</td><td>116</td><td>67</td><td>49</td><td></td><td>56</td><td>60</td><td></td></tr><tr><td> N1</td><td>91</td><td>35</td><td>56</td><td></td><td>48</td><td>43</td><td></td></tr><tr><td> N2</td><td>40</td><td>13</td><td>27</td><td></td><td>19</td><td>21</td><td></td></tr><tr><td> N3</td><td>17</td><td>5</td><td>12</td><td></td><td>4</td><td>13</td><td></td></tr><tr><td>M stage</td><td></td><td></td><td></td><td>0.355</td><td></td><td></td><td>0.751</td></tr><tr><td> M0</td><td>254</td><td>117</td><td>137</td><td></td><td>123</td><td>131</td><td></td></tr><tr><td> M1</td><td>10</td><td>3</td><td>7</td><td></td><td>4</td><td>6</td><td></td></tr><tr><td>UICC stage</td><td></td><td></td><td></td><td><0.001*</td><td></td><td></td><td>0.400</td></tr><tr><td> I</td><td>95</td><td>54</td><td>41</td><td></td><td>49</td><td>46</td><td></td></tr><tr><td> II</td><td>48</td><td>28</td><td>20</td><td></td><td>24</td><td>24</td><td></td></tr><tr><td> III</td><td>89</td><td>28</td><td>61</td><td></td><td>43</td><td>46</td><td></td></tr><tr><td> IV</td><td>32</td><td>10</td><td>22</td><td></td><td>11</td><td>21</td><td></td></tr><tr><td>Differentiation</td><td></td><td></td><td></td><td><0.001*</td><td></td><td></td><td>0.044*</td></tr><tr><td> High</td><td>47</td><td>33</td><td>14</td><td></td><td>30</td><td>17</td><td></td></tr><tr><td> Moderate</td><td>42</td><td>20</td><td>22</td><td></td><td>21</td><td>21</td><td></td></tr><tr><td> Low</td><td>175</td><td>67</td><td>108</td><td></td><td>76</td><td>99</td><td></td></tr></table> |
55d9572c26a67a4ce8e9ae364121b07ba13072c7adf21a07f54e15795a6cf9c8.png | complex | <table><tr><td></td><td colspan="2">United States</td><td>United Kingdom</td><td>Canada</td><td>International</td></tr><tr><td>Source</td><td>U.S. government</td><td>The Medical Letter</td><td>U.K. government</td><td>Canadian government</td><td>World Health Organization</td></tr><tr><td>Primaquine as Primary Prophylaxis</td><td>As an alternative to suppressive options or:With travel where malaria is primarily <i>P. vivax</i>Short-term travelShort-notice travel</td><td>Only as an alternative to suppressive options</td><td>Not recommended</td><td>Only as an alternative to suppressive options</td><td>None specified except for special risk groups (infants, pregnant women, vulnerable children in seasonal high transmission)</td></tr><tr><td>Primaquine following a diagnosis of <i>P. vivax</i></td><td>Recommended</td><td>Recommended</td><td>Recommended</td><td>Recommended</td><td>Strongly recommended</td></tr><tr><td>Primaquine following suppressive prophylaxis</td><td>Recommended</td><td>No recommendation</td><td>Not recommended</td><td>Recommended for high risk groups</td><td>No recommendation</td></tr><tr><td>References</td><td>[21]</td><td>[22, 23]</td><td>[24, 25]</td><td>[26]</td><td>[27]</td></tr></table> |
20a4501847b19a236291950a5478cb19604310cf2df938613b1913489fa0d6ae.png | complex | <table><tr><td rowspan="2">Number</td><td rowspan="2">Act</td><td colspan="3">PLS</td><td colspan="3">EN-PLS</td></tr><tr><td><i>Pred.</i></td><td>REP</td><td>PRESS</td><td><i>Pred.</i></td><td>REP</td><td>PRESS</td></tr><tr><td>1</td><td>108.33</td><td>100.04</td><td>−8.29</td><td>68.72</td><td>95.66</td><td>−12.67</td><td>160.53</td></tr><tr><td>2</td><td>105.95</td><td>109.26</td><td>3.31</td><td>10.96</td><td>101.16</td><td>−4.79</td><td>22.94</td></tr><tr><td>3</td><td>107.54</td><td>121.08</td><td>13.54</td><td>183.33</td><td>150.84</td><td>43.30</td><td>1874.89</td></tr><tr><td>4</td><td>100.00</td><td>95.54</td><td>−4.46</td><td>19.89</td><td>110.57</td><td>10.57</td><td>111.72</td></tr><tr><td>5</td><td>100.79</td><td>94.68</td><td>−6.11</td><td>37.33</td><td>97.03</td><td>−3.76</td><td>14.14</td></tr><tr><td>6</td><td>89.68</td><td>103.86</td><td>14.18</td><td>201.07</td><td>101.68</td><td>12.00</td><td>144.00</td></tr><tr><td>7</td><td>91.27</td><td>105.41</td><td>14.14</td><td>199.94</td><td>87.64</td><td>−3.63</td><td>13.18</td></tr><tr><td>8</td><td>85.32</td><td>121.30</td><td>35.98</td><td>1294.56</td><td>103.43</td><td>18.11</td><td>327.97</td></tr><tr><td>9</td><td>101.87</td><td>85.91</td><td>−15.96</td><td>254.72</td><td>104.86</td><td>2.99</td><td>8.94</td></tr><tr><td>10</td><td>102.25</td><td>111.26</td><td>9.01</td><td>81.18</td><td>104.34</td><td>2.09</td><td>4.37</td></tr><tr><td>11</td><td>108.61</td><td>96.89</td><td>−11.72</td><td>137.36</td><td>112.05</td><td>3.44</td><td>11.83</td></tr><tr><td>12</td><td>116.10</td><td>102.6</td><td>−13.50</td><td>182.25</td><td>107.22</td><td>−8.88</td><td>78.85</td></tr><tr><td>13</td><td>91.76</td><td>96.31</td><td>4.55</td><td>20.70</td><td>90.37</td><td>−1.39</td><td>1.93</td></tr><tr><td>14</td><td>92.13</td><td>99.56</td><td>7.43</td><td>55.20</td><td>100.61</td><td>8.48</td><td>71.91</td></tr><tr><td>15</td><td>82.83</td><td>82.06</td><td>−0.77</td><td>0.59</td><td>86.56</td><td>3.73</td><td>13.91</td></tr><tr><td>16</td><td>82.53</td><td>85.69</td><td>3.16</td><td>9.99</td><td>82.04</td><td>−0.49</td><td>0.24</td></tr><tr><td>17</td><td>115.58</td><td>120.84</td><td>5.26</td><td>27.67</td><td>122.50</td><td>6.92</td><td>47.89</td></tr><tr><td>18</td><td>120.29</td><td>115.73</td><td>−4.56</td><td>20.79</td><td>125.46</td><td>5.17</td><td>26.73</td></tr><tr><td>19</td><td>135.14</td><td>126.63</td><td>−8.51</td><td>72.42</td><td>136.89</td><td>1.75</td><td>3.06</td></tr><tr><td>20</td><td>126.45</td><td>110.55</td><td>−15.90</td><td>252.81</td><td>121.62</td><td>−4.83</td><td>23.33</td></tr><tr><td>21</td><td>122.46</td><td>104.37</td><td>−18.09</td><td>327.25</td><td>116.8</td><td>−5.66</td><td>32.04</td></tr><tr><td>22</td><td>121.38</td><td>129.29</td><td>7.91</td><td>62.57</td><td>113.11</td><td>−8.27</td><td>68.39</td></tr><tr><td>23</td><td>119.20</td><td>122.39</td><td>3.19</td><td>10.18</td><td>133.17</td><td>13.97</td><td>195.16</td></tr><tr><td>24</td><td>102.41</td><td>120.91</td><td>18.50</td><td>342.25</td><td>99.67</td><td>−2.74</td><td>7.51</td></tr></table> |
a253bb72c5d1d7635b4e3dfd218e8b1941bddef416e270737759154bd21831bb.png | complex | <table><tr><td> </td><td colspan="9">Three primary batches</td></tr><tr><td>Time interval</td><td colspan="3">Day 0</td><td colspan="3">The 15th day</td><td colspan="3">The 30th day</td></tr><tr><td>Evaluation parameters</td><td>B-1</td><td>B-2</td><td>B-3</td><td>B-1</td><td>B-2</td><td>B-3</td><td>B-1</td><td>B-2</td><td>B-3</td></tr><tr><td>∗Hardness (Kg/cm<sup>2</sup>) ± SD</td><td>1.3 ± 0.58</td><td>1.2 ± 0.29</td><td>1.8 ± 0.29</td><td>1.4 ± 0.50</td><td>1.5 ± 0.00</td><td>1.7 ± 0.29</td><td>1.3 ± 0.5</td><td>1.5 ± 0.29</td><td>1.5 ± 0.29</td></tr><tr><td>Friability (%)</td><td>0.1</td><td>0.4</td><td>0.6</td><td>0.3</td><td>0.2</td><td>0.2</td><td>0.4</td><td>0.2</td><td>0.3</td></tr><tr><td>∗Drug content ± SD</td><td>100.8 ± 3.36</td><td>95.6 ± 2.34</td><td>93.8 ± 1.24</td><td>99.5 ± 2.14</td><td>94.5 ± 2.67</td><td>94.8 ± 1.23</td><td>98.3 ± 1.98</td><td>95.4 ± 1.65</td><td>95.7 ± 3.63</td></tr><tr><td>∗∗Disintegration time (sec) ± SD</td><td>37 ± 4.79</td><td>40 ± 3.64</td><td>35 ± 2.27</td><td>35 ± 3.60</td><td>42 ± 4.44</td><td>38 ± 2.18</td><td>40 ± 3.64</td><td>38 ± 1.05</td><td>41 ± 1.31</td></tr></table> |
e472bcc2fde8b56fd874b2099fe1db51377982620944300d67ca288823165ea0.png | complex | <table><tr><td></td><td colspan="2">Number (%) of facilities assessed in evaluation</td></tr><tr><td></td><td>2010</td><td>2012</td></tr><tr><td>Total</td><td>52</td><td>50</td></tr><tr><td>Region:</td><td></td><td></td></tr><tr><td>Tanga</td><td>6 (12)</td><td>6 (12)</td></tr><tr><td>Arusha</td><td>5 (10)</td><td>5 (10)</td></tr><tr><td>Lindi</td><td>3 (6)</td><td>3 (6)</td></tr><tr><td>Morogoro</td><td>5 (10)</td><td>5 (10)</td></tr><tr><td>Manyara</td><td>5 (10)</td><td>4 (8)</td></tr><tr><td>Iringa</td><td>4 (8)</td><td>4 (8)</td></tr><tr><td>Tabora</td><td>6 (12)</td><td>6 (12)</td></tr><tr><td>Kilimanjaro</td><td>5 (10)</td><td>5 (10)</td></tr><tr><td>Kigoma</td><td>3 (6)</td><td>3 (6)</td></tr><tr><td>Pwani</td><td>3 (6)</td><td>3 (6)</td></tr><tr><td>Mtwara</td><td>3 (6)</td><td>3 (6)</td></tr><tr><td>Ruvuma</td><td>4 (8)</td><td>4 (8)</td></tr><tr><td>Facility type:</td><td></td><td></td></tr><tr><td>Regional hospital</td><td>12 (23)</td><td>12 (24)</td></tr><tr><td>Health centre/Dispensary</td><td>40 (77)</td><td>38 (76)</td></tr></table> |
2fface8f0d6744b93867025d076d7eae8cfb238caa78efbbe19d7436077b788a.png | simple | <table><tr><td>Characteristics</td><td>Number</td><td>Percentage (95% confidence interval [CI])</td></tr><tr><td>Total <i>n</i></td><td>138</td><td></td></tr><tr><td>Median age (y)</td><td>30 (16–41)</td><td></td></tr><tr><td>Median gravidity</td><td>2 (1–9)</td><td></td></tr><tr><td>Median parity</td><td>1 (0–5)</td><td></td></tr><tr><td>Race/ethnicity</td><td></td><td></td></tr><tr><td> Non-Hispanic White</td><td>114</td><td>82.6 (75.4–88.1)</td></tr><tr><td> Non-Hispanic African-American</td><td>23</td><td>16.7 (11.3–13.8)</td></tr><tr><td> Other</td><td>1</td><td>0.7 (0–4.4)</td></tr><tr><td>Type of insurance</td><td></td><td></td></tr><tr><td> Private</td><td>97</td><td>70.3 (62.2–77.3)</td></tr><tr><td> Medical assistance</td><td>41</td><td>29.7 (22.7–37.8)</td></tr><tr><td>Obstetrical provider Type</td><td></td><td></td></tr><tr><td> Private physician</td><td>100</td><td>72.5 (64.5–79.3)</td></tr><tr><td> Maternal fetal medicine</td><td>3</td><td>2.2 (0.5–6.5)</td></tr><tr><td> OB/GYN residents</td><td>25</td><td>18.1 (12.5–25.4)</td></tr><tr><td> Midwife </td><td>8</td><td>5.8 (2.8–11.2)</td></tr><tr><td> Family practitioner</td><td>2</td><td>1.4 (0.07–5.5)</td></tr><tr><td>Type of delivery</td><td></td><td></td></tr><tr><td> Vaginal</td><td>116</td><td>84.1 (77.0–89.3)</td></tr><tr><td> Cesarean after labor</td><td>22</td><td>15.9 (10.7–23.0)</td></tr><tr><td>Patient documentation of nature of the penicillin allergy</td><td>78</td><td>56.5 (48.2–64.5)</td></tr><tr><td>Patients with documentation that they received antibiotic prophylaxis</td><td>135</td><td>97.8 (93.5–99.5)</td></tr><tr><td>Type of antibiotics received</td><td></td><td></td></tr><tr><td> Cephalosporin</td><td>41</td><td>30.4 (23.2–38.6)</td></tr><tr><td> Clindamycin</td><td>54</td><td>40 (32.1–48.4)</td></tr><tr><td> Erythromycin</td><td>2</td><td>1.5 (0.07–5.6)</td></tr><tr><td> Vancomycin</td><td>36</td><td>26.7 (19.9–34.7)</td></tr><tr><td> Penicillin</td><td>2</td><td>1.5 (0.07–5.6)</td></tr></table> |
967da558480e4eda9e17d74fc55e3cfb7c7153b06bcbcfc040babe3ca423fcec.png | complex | <table><tr><td>Characteristic</td><td>N</td><td>%</td></tr><tr><td colspan="3">VTE event type</td></tr><tr><td> Lower extremity DVT</td><td>37</td><td>37.4</td></tr><tr><td> Pulmonary embolism</td><td>26</td><td>26.3</td></tr><tr><td> Portal vein thrombosis</td><td>2</td><td>2</td></tr><tr><td> Upper extremity DVT</td><td>26</td><td>26.3</td></tr><tr><td> Other venous thrombotic episode</td><td>8</td><td>8.1</td></tr><tr><td>Median time to thrombocytopenia (days)</td><td>89.5</td><td>NA</td></tr></table> |
07ed4e09f06c988970792fbc0bd90e842b2cb27b2edb0466293eb490d459ab93.png | complex | <table><tr><td></td><td colspan="4">Karnataka state</td><td colspan="4">Uttar Pradesh state</td></tr><tr><td></td><td colspan="2">Bagalkot</td><td colspan="2">Hassan</td><td colspan="2">Agra</td><td colspan="2">Gorakhpur</td></tr><tr><td>% API</td><td>OXYTOCIN (%)</td><td>METHYL-ERGOMETRINE (%)</td><td>OXYTOCIN (%)</td><td>METHYL-ERGOMETRINE (%)</td><td>OXYTOCIN (%)</td><td>METHYL- ERGOMETRINE (%)</td><td>OXYTOCIN (%)</td><td>METHYL- ERGOMETRINE (%)</td></tr><tr><td>0%-25%</td><td>0.0</td><td>0.0</td><td>8.9</td><td>0.0</td><td>2.0</td><td>2.0</td><td>0.0</td><td>2.0</td></tr><tr><td>26-50%</td><td>0.0</td><td>9.5</td><td>2.2</td><td>0.0</td><td>6.0</td><td>2.0</td><td>0.0</td><td>0.0</td></tr><tr><td>51%-75%</td><td>4.2</td><td>7.1</td><td>4.4</td><td>13.0</td><td>14.0</td><td>8.0</td><td>2.0</td><td>6.0</td></tr><tr><td>76%-89%</td><td>27.1</td><td>83.3</td><td>22.2</td><td>82.6</td><td>16.0</td><td>42.0</td><td>10.0</td><td>36.0</td></tr><tr><td>WITHIN MANU-FACTURER SPECIFICA-TION (90%-110%)</td><td>66.7</td><td>0.0</td><td>60.0</td><td>4.3</td><td>50.0</td><td>46.0</td><td>78.0</td><td>56.0</td></tr><tr><td>111%-120%</td><td>2.1</td><td>0.0</td><td>2.2</td><td>0.0</td><td>12.0</td><td>0.0</td><td>8.0</td><td>0.0</td></tr><tr><td>Missing data</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>0.0</td><td>2.0</td><td>0.0</td></tr><tr><td>TOTAL</td><td>100.0</td><td>100.0</td><td>100.0</td><td>100.0</td><td>100.0</td><td>100.0</td><td>100.0</td><td>100.0</td></tr><tr><td>% Out of specification</td><td>33.0</td><td>100.0</td><td>40.0</td><td>95.7</td><td>50.0</td><td>54.0</td><td>22.0</td><td>44.0</td></tr><tr><td>Median API</td><td>98.5</td><td>84.4</td><td>98.7</td><td>85.8</td><td>99.0</td><td>89.2</td><td>102.9</td><td>90.4</td></tr><tr><td>N of ampoules of analysis</td><td>48</td><td>42</td><td>45</td><td>46</td><td>50</td><td>50</td><td>50</td><td>50</td></tr></table> |
ec639c5c7906a2f6d55d0d4a758d7b3da83f28db24db4c942be9da63c73ef746.png | simple | <table><tr><td>Variable</td><td>Frequency</td><td>Percentage</td></tr><tr><td>Recording condition of the baby after birth</td><td></td><td></td></tr><tr><td> Yes</td><td>203</td><td>84.9</td></tr><tr><td> No</td><td>36</td><td>15.1</td></tr><tr><td>Mode of delivery</td><td></td><td></td></tr><tr><td> SVD</td><td>181</td><td>75.7</td></tr><tr><td> C/S</td><td>23</td><td>9.6</td></tr><tr><td> Note recorded</td><td>35</td><td>14.6</td></tr><tr><td>Fetal outcome</td><td></td><td></td></tr><tr><td> Alive</td><td>192</td><td>80.3</td></tr><tr><td> Dead</td><td>3</td><td>1.3</td></tr><tr><td> Not recorded</td><td>44</td><td>18.4</td></tr><tr><td>Active management of third stage of labour</td><td></td><td></td></tr><tr><td> Yes</td><td>133</td><td>55.6</td></tr><tr><td> No</td><td>106</td><td>44.4</td></tr><tr><td>Sex of the new born</td><td></td><td></td></tr><tr><td> Recorded</td><td>189</td><td>79.1</td></tr><tr><td> Not recorded</td><td>50</td><td>20.9</td></tr><tr><td>Weight of the new born</td><td></td><td></td></tr><tr><td> Recorded</td><td>192</td><td>80.3</td></tr><tr><td> Not recorded</td><td>47</td><td>19.7</td></tr><tr><td>Time of delivery</td><td></td><td></td></tr><tr><td> Recorded</td><td>202</td><td>84.5</td></tr><tr><td> Not recorded</td><td>37</td><td>15.5</td></tr><tr><td>APGAR score</td><td></td><td></td></tr><tr><td>Good (7–10)</td><td>195</td><td>81.6</td></tr><tr><td>Not good (1–6)</td><td>3</td><td>1.3</td></tr><tr><td>Not recorded</td><td>41</td><td>17.2</td></tr></table> |
df02c855d87bd1a0f4583b22dfa1b3c02153cc5fcc24f7305b334cf8ca86965e.png | simple | <table><tr><td> </td><td>Family worries or complains about alcohol use</td><td>Alcohol use causing problems with others</td><td>Alcohol interfered with responsibilities</td><td>Drinking ever interfered with work/school/job/home</td><td>Drinking problem causing family/friend argues/problems</td></tr><tr><td> </td><td>OR (95% CI)</td><td>OR (95% CI)</td><td>OR (95% CI)</td><td>OR (95% CI)</td><td>OR (95% CI)</td></tr><tr><td>Sex</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Male</td><td>2.70 (2.47–2.96)</td><td>3.24 (2.35–4.47)</td><td>2.56 (1.86–3.53)</td><td>0.98 (0.82–1.17)</td><td>1.08 (0.90–1.30)</td></tr><tr><td> Female</td><td>1</td><td>1</td><td>1</td><td> </td><td> </td></tr><tr><td>Age (group)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> ≤34 years</td><td>2.05 (1.71–2.46)</td><td>2.57 (1.36–4.85)</td><td>5.63 (2.46–12.91)</td><td>2.03 (1.36–3.03)</td><td>1.23 (0.85–1.79)</td></tr><tr><td> 35–49 years</td><td>2.75 (2.30–3.29)</td><td>2.33 (1.22–4.45)</td><td>4.15 (1.78–9.65)</td><td>2.07 (1.39–3.09)</td><td>1.75 (1.21–2.54)</td></tr><tr><td> 50–64 years</td><td>2.19 (1.18–2.66)</td><td>2.12 (1.07–4.20)</td><td>1.77 (0.68–4.56)</td><td>1.91 (1.25–2.91)</td><td>1.84 (1.23–2.75)</td></tr><tr><td> ≥65 years</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Education (years)</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> 0–11</td><td>2.24 (1.96–2.58)</td><td>1.82 (1.15–2.87)</td><td>0.72 (0.44–1.17)</td><td>1.06 (0.81–1.39)</td><td>1.38 (1.05–1.81)</td></tr><tr><td> 12</td><td>1.71 (1.50–1.96)</td><td>1.30 (0.83–2.03)</td><td>0.73 (0.48–1.13)</td><td>1.06 (0.82–1.39)</td><td>1.29 (0.99–1.68)</td></tr><tr><td> 13–15</td><td>1.66 (1.45–1.91)</td><td>1.36 (0.86–2.14)</td><td>1.07 (0.72–1.60)</td><td>1.05 (0.80–1.37)</td><td>1.34 (1.02–1.76)</td></tr><tr><td> ≥16</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Income</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> <$20,000</td><td>1.37 (1.22–1.53)</td><td>1.12 (0.75–1.68)</td><td>1.05 (0.70–1.55)</td><td>0.86 (0.70–1.07)</td><td>0.95 (0.77–1.18)</td></tr><tr><td> $20,000–29,999</td><td>1.17 (1.01–1.35)</td><td>1.39 (0.86–2.24)</td><td>0.77 (0.44–1.37)</td><td>1.05 (0.80–1.39)</td><td>0.85 (0.64–1.13)</td></tr><tr><td> $30,000–49,999</td><td>1.19 (1.04–1.35)</td><td>1.16 (0.75–1.80)</td><td>1.12 (0.73–1.71)</td><td>1.06 (0.84–1.34)</td><td>0.85 (0.67–1.08)</td></tr><tr><td> ≥$50,000</td><td>1</td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Ethnicity</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Non-Hispanic black</td><td>0.81 (0.73–090)</td><td>0.52 (0.35–0.78)</td><td>0.49 (0.32–0.73)</td><td>0.77 (0.63–0.95)</td><td>0.75 (0.61–0.92)</td></tr><tr><td> Hispanic/others</td><td>0.65 (0.58–0.72)</td><td>0.80 (0.57–1.13)</td><td>0.72 (0.50–1.03)</td><td>1.06 (0.86–1.31)</td><td>0.91 (0.73–1.12)</td></tr><tr><td> Non-Hispanic white</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Physical health rating</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Good</td><td>1.34 (1.16–1.54)</td><td>1.02 (0.62–1.67)</td><td>1.45 (0.92–2.29)</td><td>1.24 (0.94–1.64)</td><td>1.22 (0.92–1.61)</td></tr><tr><td> Fair/poor</td><td>2.02 (1.75–2.33)</td><td>1.60 (0.98–2.62)</td><td>0.97 (0.53–1.76)</td><td>1.05 (0.79–1.39)</td><td>1.06 (0.80–1.40)</td></tr><tr><td> Very good/excellent</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Mental health rating</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Good</td><td>1.59 (1.39–1.82)</td><td>1.26 (0.77–2.06)</td><td>1.01 (0.61–1.67)</td><td>1.01 (0.77–1.32)</td><td>1.08 (0.82–1.41)</td></tr><tr><td> Fair/poor</td><td>2.63 (2.24–3.08)</td><td>2.56 (1.51–4.36)</td><td>1.60 (0.87–2.94)</td><td>0.97 (0.72–1.32)</td><td>1.25 (0.92–1.70)</td></tr><tr><td> Very good/excellent</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr><tr><td>Smoke</td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td> Yes</td><td>1.51 (1.19–1.92)</td><td>1.70 (0.66–4.37)</td><td>1.39 (0.52–3.68)</td><td>0.77 (0.50–1.17)</td><td>0.77 (0.50–1.18)</td></tr><tr><td> No</td><td>1</td><td>1</td><td>1</td><td>1</td><td>1</td></tr></table> |
e405a87c2b8309adb504d100ee1f232f240daa17b35303da00ff4eba4d039b01.png | complex | <table><tr><td>Variables</td><td><i>n</i> with information</td><td>%</td></tr><tr><td><i>Place of residence</i></td><td> </td><td> </td></tr><tr><td>Plak-Ô</td><td>33</td><td>66.0</td></tr><tr><td>Terra Nova</td><td>64</td><td>34.0</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Gender</i></td><td> </td><td> </td></tr><tr><td>Male</td><td>44</td><td>45.4</td></tr><tr><td>Female</td><td>53</td><td>54.6</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Age</i></td><td> </td><td> </td></tr><tr><td><2 years</td><td>32</td><td>33.0</td></tr><tr><td>≥2 years</td><td>65</td><td>67.0</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Garbage collection</i></td><td> </td><td> </td></tr><tr><td>Adequate</td><td>-</td><td>-</td></tr><tr><td>Inadequate</td><td>97</td><td>100.0</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Birthplace</i>a</td><td> </td><td> </td></tr><tr><td>Maternity/hospital</td><td>94</td><td>97.9</td></tr><tr><td>Home</td><td>2</td><td>2.1</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Vitamin A supplementation</i>a</td><td> </td><td> </td></tr><tr><td>Yes</td><td>67</td><td>77.0</td></tr><tr><td>No</td><td>20</td><td>23.0</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Iron deficiency anemia</i></td><td> </td><td> </td></tr><tr><td>No</td><td>41</td><td>42.3</td></tr><tr><td>Yes</td><td>56</td><td>57.7</td></tr><tr><td colspan="3"> </td></tr><tr><td><i>Presence of parasitic infestation</i>a</td><td> </td><td> </td></tr><tr><td>No</td><td>24</td><td>32.9</td></tr><tr><td>Yes</td><td>49</td><td>67.1</td></tr></table> |
08b0905fa8ef38b8da2174f94bec156ea6b5cf8955607b6c03063ce3c4c2f4b3.png | complex | <table><tr><td> </td><td> </td><td colspan="2">MCT4</td><td colspan="2">PDK1</td><td colspan="2">CAIX</td><td colspan="2">MCT1/MCT4*</td></tr><tr><td>Variable</td><td>n</td><td>%</td><td><i>p</i></td><td>%</td><td><i>p</i></td><td>%</td><td><i>p</i></td><td>%</td><td><i>p</i></td></tr><tr><td>PSA (ng/ml)</td><td> </td><td> </td><td>0.296</td><td> </td><td>0.451</td><td> </td><td>0.250</td><td> </td><td>0.525</td></tr><tr><td>≤ 5.0</td><td>245</td><td>47.9</td><td> </td><td>16.2</td><td> </td><td>85.9</td><td> </td><td>27.1</td><td> </td></tr><tr><td>>5.0</td><td>123</td><td>44.0</td><td> </td><td>17.5</td><td> </td><td>82.2</td><td> </td><td>27.5</td><td> </td></tr><tr><td>pT</td><td> </td><td> </td><td>0.445</td><td> </td><td>0.258</td><td> </td><td>0.522</td><td> </td><td>0.009</td></tr><tr><td>2</td><td>359</td><td>40.2</td><td> </td><td>18.7</td><td> </td><td>86.4</td><td> </td><td>20.8</td><td> </td></tr><tr><td>3</td><td>99</td><td>41.7</td><td> </td><td>15.2</td><td> </td><td>86.9</td><td> </td><td>33.3</td><td> </td></tr><tr><td>Perineural</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Invasion</td><td> </td><td> </td><td>0.155</td><td> </td><td>0.069</td><td> </td><td>0.399</td><td> </td><td>0.255</td></tr><tr><td>Absent</td><td>119</td><td>45.4</td><td> </td><td>13.4</td><td> </td><td>85.8</td><td> </td><td>26.9</td><td> </td></tr><tr><td>Present</td><td>327</td><td>39.4</td><td> </td><td>19.8</td><td> </td><td>87.2</td><td> </td><td>23.3</td><td> </td></tr><tr><td>Biochemical</td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td><td> </td></tr><tr><td>Recurrence</td><td> </td><td> </td><td>0.104</td><td> </td><td>0.176</td><td> </td><td>0.003</td><td> </td><td>0.052</td></tr><tr><td>Absent</td><td>410</td><td>40.2</td><td> </td><td>18.5</td><td> </td><td>75.4</td><td> </td><td>22.6</td><td> </td></tr><tr><td>Present</td><td>69</td><td>49.3</td><td> </td><td>13.0</td><td> </td><td>89.0</td><td> </td><td>32.8</td><td> </td></tr></table> |
e4e3f47fef007b1353c7b8efa484d73f13ad9dbcdab6d5eda5f0796790251997.png | complex | <table><tr><td></td><td colspan="4">Single mothers (n = 442)</td><td colspan="4">Partnered mothers (n = 2218)</td><td colspan="4">All mothers (n = 2660)</td></tr><tr><td></td><td colspan="2">Moderate (n = 115) vs. non-smoking (n = 236)</td><td colspan="2">Heavy (n = 91) vs. non-smoking (n = 236)</td><td colspan="2">Moderate (n = 413) vs. non-smoking (n = 1607)</td><td colspan="2">Heavy (n = 198) vs. non-smoking (n = 1607)</td><td colspan="2">Moderate (n = 528) vs. non-smoking (n = 1843)</td><td colspan="2">Heavy (n = 289) vs. non-smoking (n = 1843)</td></tr><tr><td>Coping styles</td><td>OR</td><td>CI 95%</td><td>OR</td><td>CI 95%</td><td>OR</td><td>CI 95%</td><td>OR</td><td>CI 95%</td><td>OR</td><td>CI 95%</td><td>OR</td><td>CI 95%</td></tr><tr><td>Substance consumption</td><td>1.54</td><td>1.38-1.72</td><td>1.80</td><td>1.58-2.04</td><td>1.51</td><td>1.44-1.58</td><td>1.66</td><td>1.55-1.78</td><td>1.51</td><td>1.45-1.58</td><td>1.72</td><td>1.62-1.82</td></tr><tr><td>Self-blame/rumination</td><td>1.04</td><td>0.93-1.16</td><td>1.24</td><td>1.10-1.40</td><td>0.98</td><td>0.93-1.04</td><td>1.00</td><td>0.94-1.07</td><td>0.99</td><td>0.95-1.04</td><td>1.06</td><td>1.00-1.12</td></tr><tr><td>Blaming others</td><td>1.07</td><td>0.95-1.20</td><td>0.94</td><td>0.84-1.06</td><td>0.96</td><td>0.90-1.02</td><td>0.99</td><td>0.91-1.07</td><td>0.99</td><td>0.94-1.04</td><td>0.97</td><td>0.91-1.03</td></tr><tr><td>Positive self-verbalisation</td><td>1.07</td><td>0.96-1.19</td><td>1.11</td><td>0.98-1.25</td><td>1.02</td><td>0.97-1.07</td><td>0.97</td><td>0.91-1.04</td><td>1.03</td><td>0.99-1.08</td><td>1.03</td><td>0.98-1.09</td></tr><tr><td>Active influence</td><td>1.19</td><td>1.04-1.37</td><td>1.08</td><td>0.94-1.25</td><td>1.03</td><td>0.97-1.10</td><td>1.03</td><td>0.94-1.13</td><td>1.05</td><td>0.99-1.11</td><td>1.02</td><td>0.95-1.09</td></tr></table> |
3dd12ab0ee1a21dcb38955df81c5ba4b578ee16dcea0d0efef3342b3d37b5a9d.png | simple | <table><tr><td>Genetic model</td><td>Pooled OR (95% CI)</td><td><i>P</i>-value</td><td>Study number</td><td>T2DM size</td><td>Control size</td><td><i>P</i><sub>heterogeneity(<i>I2%</i>)</sub></td></tr><tr><td>Allelic genetic model</td><td>1.350 (1.270–1.420)</td><td><0.00001*</td><td>10</td><td>7607</td><td>8129</td><td>0.07 (42.9%)</td></tr><tr><td>Chinese subgroup</td><td>1.350 (1.270–1.430)</td><td><0.00001*</td><td>6</td><td>5079</td><td>5880</td><td>0.01 (66.7%)</td></tr><tr><td>Korean subgroup</td><td>1.300 (1.100–1.520)</td><td>0.002*</td><td>1</td><td>865</td><td>496</td><td>NA</td></tr><tr><td>Indian subgroup</td><td>1.510 (1.000–2.300)</td><td>0.05</td><td>2</td><td>1429</td><td>1576</td><td>1.0 (0%)</td></tr><tr><td>Malaysian subgroup</td><td>1.450 (1.070–1.960)</td><td>0.02*</td><td>1</td><td>234</td><td>177</td><td>NA</td></tr><tr><td>Recessive genetic model</td><td>0.650 (0.570–0.730)</td><td><0.00001*</td><td>10</td><td>7607</td><td>8129</td><td>0.79 (0%)</td></tr><tr><td>Chinese subgroup</td><td>0.640 (0.560–0.730)</td><td><0.00001*</td><td>6</td><td>5079</td><td>5880</td><td>0.38 (5.6%)</td></tr><tr><td>Korean subgroup</td><td>0.680 (0.490–0.950)</td><td>0.02*</td><td>1</td><td>865</td><td>496</td><td>NA</td></tr><tr><td>Indian subgroup</td><td>0.790 (0.100–6.160)</td><td>0.82</td><td>2</td><td>1429</td><td>1576</td><td>1.0 (0%)</td></tr><tr><td>Malaysian subgroup</td><td>0.660 (0.350–1.270)</td><td>0.22</td><td>1</td><td>234</td><td>177</td><td>NA</td></tr><tr><td>Dominant genetic model</td><td>1.450 (1.286–1.634)</td><td><0.00001*</td><td>10</td><td>7607</td><td>8129</td><td><0.044* (48.1%)</td></tr><tr><td>Chinese subgroup</td><td>1.424 (1.198–1.692)</td><td><0.00001*</td><td>6</td><td>5079</td><td>5880</td><td>0.005 (70.5%)</td></tr><tr><td>Korean subgroup</td><td>1.410 (1.124–1.768)</td><td>0.003*</td><td>1</td><td>865</td><td>496</td><td>NA</td></tr><tr><td>Indian subgroup</td><td>1.509 (0.986–2.309)</td><td>0.058</td><td>2</td><td>1429</td><td>1576</td><td>0.907 (0%)</td></tr><tr><td>Malaysian subgroup</td><td>1.616 (1.091–2.395)</td><td>0.017*</td><td>1</td><td>234</td><td>177</td><td>NA</td></tr><tr><td>Additive genetic model</td><td>1.346 (1.275–1.422)</td><td><0.00001*</td><td>10</td><td>7607</td><td>8129</td><td><0.072 (42.9%)</td></tr><tr><td>Chinese subgroup</td><td>1.344 (1.187–1.522)</td><td><0.00001*</td><td>6</td><td>5079</td><td>5880</td><td>0.01 (66.7%)</td></tr><tr><td>Korean subgroup</td><td>1.296 (1.102–1.524)</td><td>0.002*</td><td>1</td><td>865</td><td>496</td><td>NA</td></tr><tr><td>Indian subgroup</td><td>1.513 (0.998–2.295)</td><td>0.051</td><td>2</td><td>1429</td><td>1576</td><td>0.999 (0%)</td></tr><tr><td>Malaysian subgroup</td><td>1.448 (1.068–1.962)</td><td>0.017*</td><td>1</td><td>234</td><td>177</td><td>NA</td></tr></table> |
3b5b0a513c09eb2d13587e58c4769767901a8312160f3f942882e3b7faf98f7f.png | complex | <table><tr><td></td><td colspan="2">Habituation</td><td colspan="2">Extinction</td></tr><tr><td></td><td>CS+</td><td>CS−</td><td>CS+</td><td>CS− </td></tr><tr><td>SC measurement first</td><td>0.020 (0.019)</td><td>0.006 (0.019)</td><td>0.025 (0.030)</td><td>−0.064 (0.026) </td></tr><tr><td>SC measurement second</td><td>0.021 (0.017)</td><td>0.023 (0.019)</td><td>0.014 (0.018)</td><td>−0.029 (0.006) </td></tr><tr><td>SC measurement third</td><td>−0.008 (0.015)</td><td>0.027 (0.020)</td><td>0.013 (0.012)</td><td>0.007 (0.011) </td></tr><tr><td>SC measurement fourth</td><td>−0.002 (0.005)</td><td>−0.005 (0.005)</td><td>0.004 (0.008)</td><td>−0.025 (0.024) </td></tr></table> |
e7f660612c9aff78de29fa5559bc98cf9a5e83bcfbefb6029d52d0d843433c62.png | simple | <table><tr><td>Gene</td><td>Forward Primer</td><td>Reverse Primer</td></tr><tr><td>Slc22a1</td><td>TCTGGCTACAGGAGAACGACGGCCA</td><td>TGCTCCATTATCCTGACAGCTCGCGT</td></tr><tr><td>Slc22a2</td><td>TCGAAACAGAGGAGGATTGTGGGAATA</td><td>GAGAGGTGTTTCCCATTGCACTTAGCCAC</td></tr><tr><td>Slc22a6</td><td>TATGTGGGCACCTTGATTGGC</td><td>AGGGTGAGGTCCAGCCTTCCT</td></tr><tr><td>Slc22a8</td><td>ATCTCATCAACATCTATTGGG</td><td>AGGGCCTTTGAGTATTTTCCA</td></tr><tr><td>Slco1a1</td><td>TATGGAGGACAAGCCAGAGAG</td><td>AGAGGTGGTTAATCCAGCAAC</td></tr><tr><td>Slco1a2</td><td>CACAGAAAAAAGGCCAAGGAA</td><td>TAAGGAAAGACAGAAGGTACT</td></tr><tr><td>Slco1a5</td><td>CACAGAGAAAAAGCCAAAGAG</td><td>AGAGGCAGTTAAGCCGGCAAC</td></tr></table> |
1e72c9c26cd296b2d0d81f2cbbed4114d1c2f35074dec945fdbfdccd6fa9d67d.png | simple | <table><tr><td> </td><td>Score cutpoint</td><td>Sensitivity (%)</td><td>Specificity (%)</td><td>LR+</td><td>AUC (95% CI)</td></tr><tr><td>Total delay</td><td>40</td><td>74.68</td><td>48.81</td><td>1.46</td><td>0.62 (0.57-0.69)</td></tr><tr><td>Patient delay</td><td>55</td><td>66.67</td><td>77.80</td><td>3.00</td><td>0.72 (0.61-0.84)</td></tr><tr><td>Provider delay</td><td>40</td><td>81.17</td><td>20.24</td><td>1.02</td><td>0.51 (0.46-0.55)</td></tr></table> |
658a07c62767f1f7a4a0dd9fd26a1ce5a84e44996c9de3bf75d2ad6f4dd47d48.png | simple | <table><tr><td>Mycotoxigenic Fungi</td><td>Corn Silage</td><td>Barley Silage</td><td>Hay</td></tr><tr><td><i>Fusarium culmorum</i></td><td>100</td><td>0</td><td>0</td></tr><tr><td><i>F. poae</i></td><td>0</td><td>100</td><td>100</td></tr><tr><td><i>F. verticillioides</i></td><td>0</td><td>100</td><td>0</td></tr><tr><td><i>F. sporotrichioides</i></td><td>0</td><td>100</td><td>0</td></tr><tr><td><i>Aspergillus</i><i>flavus</i></td><td>100</td><td>20</td><td>0</td></tr><tr><td><i>Penicillium roqueforti</i></td><td>100</td><td>100</td><td>100</td></tr><tr><td><i>P. crustosum</i></td><td>20</td><td>0</td><td>20</td></tr><tr><td><i>P. paneum</i></td><td>20</td><td>0</td><td>20</td></tr><tr><td><i>P. citrinum</i></td><td>50</td><td>25</td><td>0</td></tr></table> |
efde1f3cb42513a316442dead41b56d0cc02ba8b11fd600288132d8542ac80a7.png | simple | <table><tr><td>Author</td><td>N</td><td>Year</td><td>ICU</td><td>Language</td><td>DeliriumN (%)</td><td>Sensitivity</td><td>Specificity</td><td>APACHE II</td><td>QUADAS</td></tr><tr><td>Ely [19]</td><td>38</td><td>2001</td><td>MedicalCoronary</td><td>English</td><td>33 (87)<sup>1</sup></td><td>100 (95.2 to 100)</td><td>100 (79.4 to 100)</td><td>17.1 ± 8.7<sup>#</sup></td><td>13</td></tr><tr><td>Ely [18]</td><td>96</td><td>2001</td><td>Medical Coronary</td><td>English</td><td>(25.2)<sup>2</sup></td><td>100 (95.4 to 100)</td><td>88.8 (83.8 to 92.7)</td><td>23 (18 to 29)*</td><td>13</td></tr><tr><td>Lin [7]</td><td>102</td><td>2004</td><td>Medical</td><td>Chinese</td><td>22 (22.4)</td><td>95.5 (77.2 to 99.9)</td><td>97.5 (91.3 to 99.7)</td><td>NR</td><td>13</td></tr><tr><td>van Eijk [17]</td><td>126</td><td>2009</td><td>General</td><td>English Dutch</td><td>43 (34)</td><td>64.3 (48.0 to 78.4)</td><td>88.8 (79.0 to 94.1)</td><td>20. 9 ± 7.5<sup>#</sup></td><td>14</td></tr><tr><td>Luetz [4]</td><td>156</td><td>2010</td><td>Surgical</td><td>German</td><td>63 (40)</td><td>78.8 (72.0 to 84.5)</td><td>97.1 (94.9 to 98.5)</td><td>16 (13 to 19)*</td><td>14</td></tr><tr><td>Heo [11]</td><td>22</td><td>2011</td><td>Medical</td><td>Korean</td><td>16 (72.7)</td><td>89.5 (78.5 to 98.0)</td><td>71.4 (47.8 to 88.7)</td><td>25.5 (9 to 39)*</td><td>13</td></tr><tr><td>van Eijk [14]</td><td>181</td><td>2011</td><td>MedicalSurgical</td><td>English Dutch</td><td>80 (28.3)</td><td>46.7 (35.1 to 58.6)</td><td>98.1 (93.4 to 99.8)</td><td>18.6 ± 7.5<sup>#</sup></td><td>13</td></tr><tr><td>Gusmao-Flores [9]</td><td>119</td><td>2011</td><td>MedicalSurgical</td><td>Portuguese</td><td>46 (38.6)</td><td>72.5 (56.1 to 85.4)</td><td>96.2 (89.3 to 99.2)</td><td>15 ± 6<sup>#</sup></td><td>14</td></tr><tr><td>Mitasova [10]</td><td>129</td><td>2012</td><td>Stroke Unit</td><td>Czech</td><td>55 (42.6)<sup>1</sup></td><td>78.9 (73.7 to 83.5)</td><td>98.3 (97.1 to 99.1)</td><td>NR</td><td>14</td></tr></table> |
3191a50ea803593d70d245b2e7cf0ba568cccf7433f81f50f3a2cf862dcde8bb.png | complex | <table><tr><td rowspan="3">Total PSA</td><td colspan="2">Prostate cancer</td></tr><tr><td>No</td><td>Yes</td></tr><tr><td>2-2.9</td><td>4 (6.2%)</td><td>5 (7.7%)</td></tr><tr><td>3-3.9</td><td>6 (9.4%)</td><td>8 (12.3%)</td></tr><tr><td>4+</td><td>54 (84.4%)</td><td>52 (80.0%)</td></tr></table> |
0d704197fa69ef31b77eae1d31148f38b979bc5463e35a40842089e71c051267.png | simple | <table><tr><td>ICD-9 procedure code</td><td>N = 50,225^ n (%)</td><td>Description</td></tr><tr><td>41.31</td><td>5,185 (10.3%)</td><td>Biopsy of bone marrow</td></tr><tr><td>38.93</td><td>4,066 (8.1%)</td><td>Venous catheterization, not elsewhere classified</td></tr><tr><td>01.59</td><td>3,160 (6.3%)</td><td>Other excision or destruction of lesion or tissue of brain</td></tr><tr><td>03.31</td><td>2,705 (5.4%)</td><td>Spinal tap</td></tr><tr><td>86.07</td><td>2,264 (4.5%)</td><td>Insertion of totally implantable vascular access device [VAD]</td></tr><tr><td>85.05</td><td>1,147 (2.3%)</td><td>Incision with removal of foreign body or device from skin and subcutaneous tissue</td></tr><tr><td>02.2</td><td>1,076 (2.1%)</td><td>Ventriculostomy</td></tr><tr><td>40.11</td><td>1,038 (2.1%)</td><td>Biopsy of lymphatic structure</td></tr><tr><td>40.3</td><td>827 (1.7%)</td><td>Regional lymph node excision</td></tr><tr><td>54.4</td><td>819 (1.6%)</td><td>Excision or destruction of peritoneal tissue</td></tr></table> |
44f96c4255c84f31c6b639875920e807cb001f012a98d84b27f011375d1cea9b.png | simple | <table><tr><td>Recommended timeline</td><td>Building the infrastructure</td><td>Educational development</td><td>Program accreditation</td><td>Marketing and recruitment</td></tr><tr><td>6–12 months</td><td>Institutional affiliation and training site</td><td></td><td></td><td></td></tr><tr><td></td><td>Budget/funding Timeline</td><td></td><td></td><td></td></tr><tr><td>3–4 months</td><td></td><td>Review and apply ACGME requirements</td><td></td><td></td></tr><tr><td></td><td></td><td>Develop your educational vision</td><td></td><td></td></tr><tr><td>4–6 months</td><td></td><td>Curriculum and program design</td><td>Complete the application</td><td></td></tr><tr><td>2–3 months</td><td></td><td>Faculty development</td><td>Prepare for site visit</td><td></td></tr><tr><td>3–6 months</td><td></td><td></td><td>Await accreditation decision</td><td>Strategic marketing</td></tr><tr><td>8 months (July–February)</td><td></td><td></td><td></td><td>Active recruitment</td></tr><tr><td>4 Months (March–June)</td><td></td><td></td><td></td><td>The beginning: match and orientation</td></tr></table> |
abb1da8dd8fe0418bfeee08b08ff8e33fa459db85b793fb6990a30401f962f0f.png | complex | <table><tr><td>RCC subtype</td><td>%</td><td>Number of samples</td></tr><tr><td>Clearcell RCC</td><td>48%</td><td>(17/35)</td></tr><tr><td>Papillary RCC</td><td>32%</td><td>(11/35)</td></tr><tr><td>Chromophobe RCC</td><td>20%</td><td>(7/35)</td></tr><tr><td colspan="3">TNM</td></tr><tr><td>T1a</td><td>31%</td><td>(11/35)</td></tr><tr><td>T1b</td><td>23%</td><td>(8/35)</td></tr><tr><td>T2</td><td>8%</td><td>(3/35)</td></tr><tr><td>T3a</td><td>26%</td><td>(9/35)</td></tr><tr><td>T3b</td><td>12%</td><td>(4/35)</td></tr><tr><td>N0</td><td>65%</td><td>(23/35)</td></tr><tr><td>N1</td><td>23%</td><td>(8/35)</td></tr><tr><td>N2</td><td>12%</td><td>(4/35)</td></tr><tr><td colspan="3">Fuhrman’s Classification</td></tr><tr><td>Grade 1</td><td>8%</td><td>(3/35)</td></tr><tr><td>Grade 2</td><td>43%</td><td>(15/35)</td></tr><tr><td>Grade 3</td><td>49%</td><td>(17/35)</td></tr></table> |
4956e3473ab5bb2f85426705fdb963ad0e157901b074d2e4d75c0cf922e886bc.png | simple | <table><tr><td>Harvestable amount</td><td>pH</td><td>OM</td><td>TN </td><td>P<sub>2</sub>O<sub>5</sub></td></tr><tr><td>Root length</td><td>0.452</td><td>0.888∗∗</td><td>0.921∗∗</td><td>0.630</td></tr></table> |
8112c54d2f96ebb8d9e0b7e2e44d572a4fc49e447b871a202ab84ed910e8f4b2.png | simple | <table><tr><td>Case</td><td>Fracture type</td><td>Time to fracture (mo)</td><td>Treatment</td><td>Plates</td><td>Bone graft</td><td>Time to union (mo)</td><td>Duration of follow-up (mo)</td><td>Outcome</td><td>JOA score</td></tr><tr><td>1</td><td>Oblique</td><td>104</td><td>ORIF</td><td>DFLCP</td><td>-</td><td>4</td><td>22</td><td>Union</td><td>63</td></tr><tr><td>2</td><td>Transverse</td><td>100</td><td>ORIF</td><td>Reverse DFLCP</td><td>Auto, fibula</td><td>6</td><td>28</td><td>Union</td><td>77</td></tr><tr><td>3</td><td>Transverse</td><td>75</td><td>Revision (IBG) +ORIF</td><td>LCP</td><td>Allo, auto, iliac</td><td>3</td><td>119</td><td>Union</td><td>68</td></tr><tr><td>4</td><td>Transverse (with stem fracture)</td><td>88</td><td>Revision (IBG)</td><td>-</td><td>Allo</td><td>4</td><td>45</td><td>Union</td><td>77</td></tr><tr><td>5</td><td>Transverse</td><td>78</td><td>ORIF</td><td>Dall-Miles plate</td><td>Auto, fibula</td><td>7</td><td>115</td><td>Nonunion*</td><td>53</td></tr><tr><td>6</td><td>Oblique</td><td>99</td><td>ORIF</td><td>LCF</td><td>Auto, iliac</td><td>4</td><td>74</td><td>Union</td><td>60</td></tr><tr><td>7</td><td>Transverse</td><td>12</td><td>ORIF</td><td>Dall-Miles plate</td><td>Auto, fibula</td><td>8</td><td>180</td><td>Union</td><td>67</td></tr><tr><td>8</td><td>Oblique</td><td>120</td><td>ORIF</td><td>DFLCP</td><td>Allo</td><td>4</td><td>35</td><td>Union</td><td>60</td></tr><tr><td>9</td><td>Oblique</td><td>142</td><td>ORIF</td><td>DFLCP</td><td>-</td><td>4</td><td>10</td><td>Union</td><td>62</td></tr><tr><td>10</td><td>Transverse</td><td>114</td><td>ORIF</td><td>Reverse DFLCP</td><td>Auto, iliac</td><td>6</td><td>12</td><td>Union</td><td>72</td></tr><tr><td>11</td><td>Oblique</td><td>240</td><td>ORIF</td><td>DFLCP</td><td>-</td><td>2</td><td>8</td><td>Union</td><td>81</td></tr></table> |
6176dbd5c31de9c5533b7218de42890cfbf835d00be39c38577b89673dd9bd09.png | complex | <table><tr><td></td><td colspan="4">Total</td></tr><tr><td>Characteristic</td><td><i>n</i></td><td>IR</td><td>IRR</td><td>95% CI</td></tr><tr><td>Total</td><td>338</td><td>0.92</td><td>NA</td><td></td></tr><tr><td>Race</td><td></td><td></td><td></td><td></td></tr><tr><td> Whites</td><td>295</td><td>0.97</td><td>1.00</td><td>Reference</td></tr><tr><td> Blacks</td><td>20</td><td>0.59</td><td>0.61</td><td>0.37 to 0.96</td></tr><tr><td> Other/unspecified</td><td>23</td><td>~</td><td>~</td><td>~</td></tr><tr><td>Calendar period</td><td></td><td></td><td></td><td></td></tr><tr><td> 1977 to 1986</td><td>79</td><td>0.78</td><td>1.00</td><td>Reference</td></tr><tr><td> 1987 to 1996</td><td>121</td><td>1.02</td><td>1.30</td><td>0.97 to 1.76</td></tr><tr><td> 1997 to 2006</td><td>138</td><td>0.96</td><td>1.23</td><td>0.93 to 1.65</td></tr><tr><td>Age</td><td></td><td></td><td></td><td></td></tr><tr><td> <50 years</td><td>59</td><td>0.25</td><td>1.00</td><td>Reference</td></tr><tr><td> ≥50 years</td><td>279</td><td>2.70</td><td>11.02</td><td>8.31 to 14.87</td></tr><tr><td>Laterality</td><td></td><td></td><td></td><td></td></tr><tr><td> Right</td><td>164</td><td>0.45</td><td>1.00</td><td>Reference</td></tr><tr><td> Left</td><td>173</td><td>0.47</td><td>1.06</td><td>0.85 to 1.32</td></tr><tr><td> Not specified</td><td>1</td><td>~</td><td>~</td><td>~</td></tr><tr><td>Site</td><td></td><td></td><td></td><td></td></tr><tr><td> Upper outer quadrant</td><td>105</td><td>0.29</td><td>1.00</td><td>Reference</td></tr><tr><td> Upper inner quadrant</td><td>29</td><td>0.08</td><td>0.28</td><td>0.18 to 0.43</td></tr><tr><td> Lower outer quadrant</td><td>23</td><td>0.06</td><td>0.22</td><td>0.13 to 0.35</td></tr><tr><td> Lower inner quadrant</td><td>14</td><td>~</td><td>~</td><td>~</td></tr><tr><td> Nipple/central</td><td>28</td><td>0.08</td><td>0.27</td><td>0.17 to 0.41</td></tr><tr><td> Overlapping</td><td>89</td><td>0.24</td><td>0.83</td><td>0.62 to 1.11</td></tr><tr><td> Not specified</td><td>50</td><td>0.14</td><td>0.47</td><td>0.33 to 0.67</td></tr><tr><td>Stage</td><td></td><td></td><td></td><td></td></tr><tr><td> Localized</td><td>320</td><td>0.87</td><td>1.00</td><td>Reference</td></tr><tr><td> Regional</td><td>14</td><td>~</td><td>~</td><td>~</td></tr><tr><td> Distant</td><td>1</td><td>~</td><td>~</td><td>~</td></tr><tr><td> Unstaged</td><td>3</td><td>~</td><td>~</td><td>~</td></tr><tr><td>LN and size<sup>a</sup></td><td></td><td></td><td></td><td></td></tr><tr><td> LN negative, ≤2 cm</td><td>126</td><td>0.50</td><td>1.00</td><td>Reference</td></tr><tr><td> LN negative, >2 cm</td><td>67</td><td>0.26</td><td>0.52</td><td>0.38 to 0.71</td></tr><tr><td> LN positive, ≤2 cm</td><td>2</td><td>~</td><td>~</td><td>~</td></tr><tr><td> LN positive, >2 cm</td><td>3</td><td>~</td><td>~</td><td>~</td></tr><tr><td> Other/not specified</td><td>46</td><td>0.18</td><td>0.36</td><td>0.25 to 0.51</td></tr><tr><td>Hormone receptors<sup>b</sup></td><td></td><td></td><td></td><td></td></tr><tr><td> ER-negative/PR-negative</td><td>128</td><td>0.56</td><td>1.00</td><td>Reference</td></tr><tr><td> ER-negative/PR-positive</td><td>6</td><td>~</td><td>~</td><td>~</td></tr><tr><td> ER-positive/PR-positive</td><td>21</td><td>0.09</td><td>0.16</td><td>0.10 to 0.25</td></tr><tr><td> ER-positive/PR-negative</td><td>12</td><td>~</td><td>~</td><td>~</td></tr><tr><td> Other/not specified</td><td>55</td><td>0.24</td><td>0.42</td><td>0.30 to 0.59</td></tr></table> |
1b3b2d62de7e566e177d0d1034c6efaeabe17c4fe422320969d21a235f1a1e9c.png | complex | <table><tr><td></td><td colspan="7">Journal Name</td><td></td></tr><tr><td></td><td>BMJ</td><td>Lancet</td><td>NEJM</td><td>JAMA</td><td>BJS</td><td>BJC</td><td>BJOG</td><td>Total</td></tr><tr><td colspan="9">2007-8</td></tr><tr><td>Original articles</td><td>6</td><td>5</td><td>5</td><td>1</td><td>10</td><td>16</td><td>10</td><td>54<sup>1 </sup>(1.6%)</td></tr><tr><td>Pilot or feasibility study in preparation for a trial</td><td>0</td><td>3</td><td>3</td><td>0</td><td>2</td><td>1</td><td>3</td><td>12</td></tr><tr><td>Piloting new technique, combination of treatments</td><td>1</td><td>0</td><td>0</td><td>0</td><td>4</td><td>2</td><td>6</td><td>13</td></tr><tr><td>Phase I, II trials</td><td>0</td><td>1</td><td>1</td><td>0</td><td>0</td><td>7</td><td>0</td><td>9</td></tr><tr><td>Piloting screening program</td><td>2</td><td>0</td><td>0</td><td>1</td><td>1</td><td>1</td><td>0</td><td>5</td></tr><tr><td>Piloting guidelines, educational package, patient care strategy</td><td>3</td><td>1</td><td>0</td><td>0</td><td>2</td><td>3</td><td>1</td><td>10</td></tr><tr><td>Laboratory testing of activity of compounds</td><td>0</td><td>0</td><td>1</td><td>0</td><td>1</td><td>2</td><td>0</td><td>4</td></tr><tr><td>Total research papers</td><td>292</td><td>379</td><td>444</td><td>383</td><td>338</td><td>1084</td><td>398</td><td>3318</td></tr><tr><td colspan="9">2000-1<sup>2</sup></td></tr><tr><td>Original articles</td><td>11</td><td>17</td><td>3</td><td>7</td><td>9</td><td>33</td><td>10</td><td>90 (2.0%)</td></tr><tr><td><i>Total research papers</i></td><td>372</td><td>1115</td><td>434</td><td>619</td><td>396</td><td>1132</td><td>381</td><td>4449</td></tr></table> |
c23aa7f384605fcd75447d90fca3d31e3cb4161ebd324968b7b2afb751978a36.png | complex | <table><tr><td>Variable</td><td>Number (percent)</td></tr><tr><td rowspan="2">Gender</td><td>Male: 7 (28%)</td></tr><tr><td>Female: 18 (72%)</td></tr><tr><td rowspan="4">Racial/ethnic background</td><td>White: 19 (76%)</td></tr><tr><td>African-American: 2 (8%)</td></tr><tr><td>Hispanic: 1 (4%)</td></tr><tr><td>Asian: 3 (12%)</td></tr><tr><td rowspan="5">Highest Education level</td><td>High School or less: 3 (12%)</td></tr><tr><td>Some college, no degree: 3 (12%)</td></tr><tr><td>Associate’s degree: 11 (44%)</td></tr><tr><td>Bachelor’s degree: 4 (16%)</td></tr><tr><td>Post-graduate training: 4 (16%)</td></tr><tr><td rowspan="4">Recruitment source</td><td>Office staff: 7 (28%)</td></tr><tr><td>Website volunteer: 8 (32%)</td></tr><tr><td>Practice volunteer: 6 (24%)</td></tr><tr><td>Department staff volunteer: 4 (16%)</td></tr><tr><td rowspan="3">Newest Vital Sign Health Literacy category</td><td>Adequate literacy: 18 (72%)</td></tr><tr><td>Possible limited literacy: 5 (20%)</td></tr><tr><td>High likelihood limited literacy: 2 (8%)</td></tr><tr><td rowspan="3">REALM grade level</td><td>High School: 21 (84%)</td></tr><tr><td>7th – 8th grade: 3 (12%)</td></tr><tr><td>4th to 6th grade: 1 (4%)</td></tr><tr><td> </td><td>Mean (sd, range)</td></tr><tr><td>Age, years</td><td>51.4, (13.8, 22 to 71)</td></tr><tr><td>Subjective numeracy scale</td><td>4 (0.75, 2.25 to 5.38)</td></tr></table> |
adb2b85a37325307c160c3799f698bfec7f5165a6943b321e692d368ee5d3e9b.png | simple | <table><tr><td></td><td>Steatosis grade</td><td>Fibrosis stage</td><td>Lobular inflammation</td><td>Ballooning</td></tr><tr><td>Serum (<i>n</i>=138)</td><td></td><td></td><td></td><td></td></tr><tr><td>Campesterol</td><td>−0.025</td><td>−0.002</td><td>−0.025</td><td>0.092</td></tr><tr><td>Sitosterol</td><td>−0.027</td><td>0.029</td><td>−0.028</td><td>0.159</td></tr><tr><td>Avenasterol</td><td>0.092</td><td>0.099</td><td>0.086</td><td>0.128</td></tr><tr><td>Sitostanol</td><td>0.100</td><td>0.026</td><td>0.098</td><td>0.024</td></tr><tr><td>Liver (<i>n</i>=38)</td><td></td><td></td><td></td><td></td></tr><tr><td>Campesterol</td><td>0.013</td><td>0.137</td><td>−0.052</td><td>0.119</td></tr><tr><td>Sitosterol</td><td>−0.392*</td><td>−0.097</td><td>−0.395*</td><td>0.054</td></tr><tr><td>Avenasterol</td><td>0.041</td><td>0.086</td><td>−0.025</td><td>−0.107</td></tr><tr><td>Sitostanol</td><td>0.650<sup>†</sup></td><td>0.215</td><td>0.407*</td><td>0.059</td></tr></table> |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.